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Background: Ulcers of the foot in people with diabetes mellitus are slow to heal and result in considerable
cost and patient suffering. The prognosis is worst for ulcers of the heel.
Objective: To assess both the clinical effectiveness and the cost-effectiveness of lightweight fibreglass
casts in the management of heel ulcers.
Design: A pragmatic, multicentre, parallel, observer-blinded randomised controlled trial. A central
randomisation centre used a computer-generated random number sequence to allocate participants
to groups.
Setting: Thirty-five specialist diabetic foot secondary care centres in the UK. Those recruited were aged
≥ 18 years and had diabetes mellitus complicated by ulcers of the heel of grades 2–4 on the National
Pressure Ulcer Advisory Panel and European Pressure Ulcer Advisory Panel scale.
Participants: In total, 509 participants [68% male, 15% with type 1 diabetes mellitus, mean age 67.5 years
(standard deviation 12.4 years)] were randomised 1 : 1 to the intervention (n = 256) or the control (n = 253)
arm. The primary outcome data were available for 425 participants (212 from the intervention arm and
213 from the control arm) and exceeded the total required; attrition was 16.5%. The median ulcer area at
baseline was 275 mm2 [interquartile range (IQR) 104–683 mm2] in the intervention group and 206 mm2
(IQR 77–649 mm2) in the control group. There were no differences between the two groups at baseline in
any parameter, neither in relation to the participant nor in relation to their ulcer.
Interventions: The intervention group received usual care supplemented by the addition of an individually
moulded, lightweight, fibreglass heel cast. The control group received usual care alone. The intervention
phase continued either until the participant’s ulcer had healed (maintained for 28 days) or for 24 weeks,
whichever occurred first. During this intervention phase, the participants were reviewed every 2 weeks,
and the fibreglass casts were replaced when they were no longer usable.
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Main outcome measures: The primary outcome measure was ulcer healing (confirmed by a blinded
observer and maintained for 4 weeks) within 24 weeks. Other outcome measures included the time taken
for the ulcer to heal, the percentage reduction in the cross-sectional area, the reduction in local pain,
amputation, survival and health economic analysis. The study was powered to define a difference in
healing of 15% (55% intervention vs. 40% control).
Results: Forty-four per cent (n = 94) of the intervention group healed within 24 weeks, compared with
37% (n = 80) of the control participants (odds ratio 1.42, 95% confidence interval 0.95 to 2.14;
p = 0.088), using an intention-to-treat analysis. No differences were observed between the two groups for
any secondary outcome.
Limitations: Although the component items of care were standardised, because this was a pragmatic
trial, usual care was not uniform. There was some evidence of a small excess of adverse events in the
intervention group; however, non-blinded observers documented these events. There was no excess of
adverse device effects.
Conclusions: There may be a small increase in healing with the use of a heel cast, but the estimate was
not sufficiently precise to provide strong evidence of an effect. There was no evidence of any subgroup in
which the intervention appeared to be particularly effective. A health economic analysis suggested that it is
unlikely that the intervention represents good value for money. The provision of a lightweight heel cast
may be of benefit to some individuals, but we have found no evidence to justify the routine adoption of
this in clinical practice.
Future work: It is unlikely that further study of this intervention will have an impact on usual clinical care,
and so future efforts should be directed towards other interventions designed to improve the healing of
ulcers in this population.
Trial registration: Current Controlled Trials ISRCTN62524796.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 34.
See the NIHR Journals Library website for further project information.
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Plain English summary
U lcers of the heel in people with diabetes mellitus present a considerable risk of limb loss throughamputation. However, one group has reported that a simple, moulded fibreglass heel cast may
improve outcomes for such people. The purpose of this study was to formally evaluate this treatment.
People with diabetes and heel ulcers attending specialist foot care centres in UK were allocated either to
continue with usual care or to be provided with a fibreglass heel cast in addition to usual care, in order
to assess whether or not the use of a cast increased the proportion of heel ulcers that healed within
24 weeks. The study was designed to see whether or not the number of ulcers healed could be increased
by at least 15% (55% vs. 40%). A health economic analysis was also undertaken.
In total, 509 people were included in the study. The mean age of the participants was 67.5 years; 68% of
the group were male and 15% of them had type 1 diabetes. Two hundred and fifty-six were allocated to
the intervention group and 253 were allocated to the control (usual care) group. The percentage of ulcers
that had healed by 24 weeks was 44% in the intervention group and 37% in the usual care group.
However, this difference was not sufficient to prove that patients with diabetes mellitus and heel ulcers
benefit from the use of fibreglass heel casts.
The health economic analysis found only very small differences between the groups, and we found no
clear evidence that the heel cast device was good value for money for the NHS.
Although the provision of a lightweight heel cast may benefit some individuals, this study found no
evidence to recommend that this be adopted in routine clinical practice.
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Scientific summary
Background
Chronic ulceration of the foot represents a major problem in people with diabetes mellitus, and ulcers
of the heel present particular difficulties, with only around 40% healing within 6 months. However, a
recent study suggested that the use of lightweight fibreglass heel casts was associated with a marked
improvement in healing time. The aim of the present study was to use a definitive, multicentre, randomised
controlled trial to compare the effectiveness of such casts in addition to usual care with usual care alone
in the management of heel ulcers of National Pressure Ulcer Advisory Panel/European Pressure Ulcer
Advisory Panel (NPUAP/EPUAP) grades 2–4 in people with type 1 or type 2 diabetes mellitus, and to explore
the cost-effectiveness of such casts.
Methods
The participants were randomised to receive either usual clinical care in a specialist centre or a fibreglass heel
cast in addition to usual care in a parallel, group design clinical trial. Randomisation was stratified by NPUAP/
EPUAP grade (depth) and ulcer cross-sectional area (< 100mm2 or ≥ 100mm2) using blocks of variable size.
The primary outcome was healing (confirmed by a blinded observer and maintained for at least 4 weeks) at
or before 24 weeks. The target sample size was 496, and based on a difference in primary outcome of 55%
(intervention) and 40% (control), allowing for 30% attrition. Secondary outcomes included the time taken
for the ulcer to heal, secondary infection, new ulceration, hospital admission, minor and major amputation
and health status. The primary analysis estimated the absolute and relative effectiveness on ulcer healing
at or before 24 weeks, comparing the intervention group with usual care. A within-trial health economic
analysis was undertaken to estimate the incremental cost per quality-adjusted life-year (QALY) and
incremental cost per percentage of healed ulcers at 24 weeks.
Results
A total of 509 participants with ulceration of the heel complicating diabetes mellitus [68% male, 15%
type 1 and 85% type 2 diabetes, mean age 67.5 years (standard deviation 12.4 years)] and attending one
of 35 specialist centres in the UK were randomised 1 : 1 to either the intervention arm (n = 256) or the
control arm (n = 253) of the study. Primary outcome data were available for 212 participants in the
intervention arm and for 213 participants in the control arm. The median (25th–75th centile) ulcer area
at baseline was 275 mm2 (104–683 mm2) in the intervention group and 206 mm2 (77–649 mm2) in the
control group, and the ulcer grades in the two groups were identical (grade 2, 32%; grade 3, 62%; and
grade 4, 6%). When analysed by intention to treat, 44% (n = 94) of the intervention group’s ulcers had
healed at or before 24 weeks, compared with 37% (n = 80) of the control group’s [odds ratio 1.42,
95% confidence interval (CI) 0.95 to 2.14; p = 0.088; risk difference 8%, 95% CI –1% to 17%; p = 0.087].
There were no differences between the two groups for any of the secondary outcome measures, including
the reduction of local pain at 2 and 4 weeks. There was no clear excess of adverse events in either group.
The results of the cost–utility analysis showed that usual care dominated the intervention, that is,
usual care had lower costs and more QALY gains under the base case (the incremental cost-effectiveness
ratio was –£35,478.95), and a one-way sensitivity analysis indicated that the intervention would be
cost-effective (£9057.89 per QALY gain) only when the lower-bound 95% CI cost estimate was used.
The probability of the intervention being cost-effective at a societal willingness-to-pay threshold of
£20,000 was estimated at 5%.
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The adjusted analysis estimated that the incremental cost of a 1% likelihood of achieving a healed ulcer
was £9.63 (£963 per additional healed heel ulcer).
Discussion
The data suggest that there may be a small increase in healing with the use of a heel cast, but the
estimate was not sufficiently precise to provide strong evidence of an effect. There was no evidence of any
subgroup in which the intervention appeared to be particularly effective. There was also no evidence of
any benefit in terms of reduced local pain. The results of the health economic analysis suggest that it is
unlikely that the intervention represents good value for money. The provision of a lightweight heel cast
may be of benefit to some individuals, but we found no evidence to justify the routine adoption of the use
of this treatment in clinical practice. It is unlikely that further study of this intervention will have an impact
on usual clinical care, and so future efforts should be directed towards other interventions designed to
improve the healing of ulcers in this population.
Trial registration
This trial is registered as ISRCTN62524796.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
The protocol has been previously published, and some sections of this earlier publication are replicated inChapters 1 and 2 under the terms of the licence granted by BioMed Central Ltd.1 © Jeffcoate et al.;
licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This
is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available
in this article, unless otherwise stated.
Foot ulcers are a major source of suffering in people with diabetes mellitus.2 They affect an estimated
15% of people with the disease, and those with foot ulcers are typically affected by other complications
of diabetes mellitus including cardiovascular, renal and eye disease. Almost 28% of ulcers have been
reported to lead to some form of amputation.3 Overall life expectancy is only 50% at 5 years after
presentation, which is lower than that for many cancers.4,5 Diabetic foot ulcers are also enormously costly
and are estimated to account for almost 0.7–0.8% of the total NHS budget in the UK.6 Only two-thirds
of all ulcers heal without amputation within 12 months, and the median time to healing for these is
78 days.7,8 Forty per cent of patients whose ulcers heal will develop a recurrence within 12 months.9
Ulcers of the heel present particular difficulties, reflected in the proverbial expression ‘heel ulcers don’t
heal’. Although 7% of heel ulcers result in amputation of the limb in diabetes mellitus and 20% persist
until death,10 a single-centre review of a consecutive series of 154 heel ulcers in 97 patients with diabetes
mellitus managed in the UK revealed that the eventual incidence of healing without surgery was very
similar to that of ulcers elsewhere on the foot. The median time to healing was, however, very much
longer at 200 days (range 24–1225 days),10 almost three times longer than that of ulcers elsewhere on
the foot. A more recent multicentre survey in 14 expert centres in Europe reported a very similar median
time to healing of heel ulcers: 237 days.11 Heel ulcers in diabetes mellitus also differ from ulcers elsewhere
on the foot in that they are frequently painful.
Although the principles of care of foot ulcers in diabetes mellitus have been promoted by the National
Institute for Health and Care Excellence (NICE), the Royal College of Nursing12 and the International Working
Group on the Diabetic Foot (International Diabetes Federation),13 there are no specific interventions that
have been shown to improve the outcome for patients with diabetes mellitus and foot ulcers. The use of a
non-removable below-knee (total contact or variant) cast is known to hasten healing in ulcers caused by
abnormal pressure loading on other parts of the foot,14 but this treatment has previously been reported to be
ineffective when the ulceration is on the heel.15
In the absence of specific treatment of proven effectiveness for heel ulcers, a small number of specialists
in the UK have started to use lightweight, removable fibreglass heel casts. Based on uncontrolled
observational evidence, it has been reported that these devices result in both a reduced time to healing
and a prompt improvement in pain. Healing was observed in 42 (84%) of a consecutive series of 50 heel
ulcers (in patients both with and without diabetes mellitus, but all with peripheral arterial disease), with a
median (range) time to healing of 6 weeks (3–13 weeks).16 The mechanism for any positive effect is not
known, but it could relate to the reduction of shearing and stretching forces applied to the surface of the
ulcer. Current strategies to reduce local forces in an area of ulceration (or an area at risk of ulceration) are
largely concentrated attempts to reduce vertical forces, with minimal, if any, effect on shear and on stretching.
Lightweight fibreglass heel casts take approximately 15 minutes to mould to the heel and can easily be
fashioned in a domiciliary setting. The casts are applied over the primary wound dressing and held in
place with an outer dressing, and they are saved and reused each time the dressing is changed. They are
replaced when stained, damaged or lost and can often be worn inside shoes. Health-care professionals can
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be trained in their use in approximately 30 minutes and the material cost of each cast is approximately £7.
On average, casts need to be replaced every 3 weeks.
The purpose of the proposed study was to determine the clinical effectiveness and cost-effectiveness of
this simple and apparently beneficial intervention, when compared with usual care.
INTRODUCTION
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Chapter 2 Methods
This was an observer-blind randomised controlled trial comparing the use of lightweight, fibreglass heelcasts in addition to usual care with usual care alone in people with diabetes mellitus complicated by
ulcers of the heel. The study was conducted in accordance with (1) independent ethics committee
approval, (2) relevant informed consent regulations (Declaration of Helsinki),17 (3) ISO (International
Organization for Standardization)-14155 guidelines,18 (4) the Data Protection Act 1998,19 (5) local
regulatory requirements with particular reference to participant safety and (6) the principles of good clinical
practice (GCP). An independent Trial Steering Committee and a Data Monitoring Committee were
convened in accordance with Medical Research Council guidelines. The study was approved by Yorkshire
and the Humber – Leeds West National Research Ethics Committee (reference 10/H1307/124) under the
UK National Integrated Research Application System. All of the participants gave written informed consent.
Protocol amendment
A major amendment to the protocol was approved on 29 March 2012. Prior to that date, if there was a
protocol violation from non-use of the heel cast by a participant allocated to the intervention arm, the
participant was withdrawn and took no further part in the study. After the amendment took effect, such a
protocol violation was noted but the participant was not withdrawn. On the same date, the protocol was
amended such that adverse events (AEs) were no longer logged, and safety was documented only by the
use of adverse device effects (ADEs) and serious adverse device effects (SADEs). The number of participants
who were randomised before and after this protocol amendment was 133 and 396, respectively. The
amended protocol has been published.1
Participants
People with diabetes mellitus and ulcers of the heel attending specialist centres in the UK were screened
for inclusion in the study. The ulcers of the heel were required to be of National Pressure Ulcer Advisory
Panel/European Pressure Ulcer Advisory Panel (NPUAP/EPUAP) grades 2, 3 or 4 (Box 1); to be affecting the
BOX 1 National Pressure Ulcer Advisory Panel/European Pressure Ulcer Advisory Panel ulcer grading system for
pressure ulcers
Grade
1. Non-blanchable erythema.
2. Partial thickness skin loss.
3. Full-thickness skin loss.
4. Full-thickness tissue loss.
5. Unstageable/unclassified: full-thickness tissue loss – depth unknown.
Note: the text of this box is reproduced from the previously published protocol,1 and is used here according to
the terms of the licence granted by BioMed Central Ltd. © Jeffcoate et al.; licensee BioMed Central Ltd. 2014.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under
the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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skin below the malleoli but overlying the calcaneum inferiorly, posteriorly, medially or laterally; and to
have been present for at least 2 weeks. The eligibility criteria, shown in Box 2, were chosen to be as
inclusive as possible; neither soft tissue infection nor mild or moderate degrees of limb ischaemia were
contraindications to inclusion. Those who met the criteria for inclusion and who provided informed written
consent were recruited and randomised to either the intervention arm, that is, to receive treatment with a
lightweight, moulded, fibreglass heel cast together with continuing usual care, or to the control arm, that
is, to continue with usual care alone (Box 3). If a person had more than one ulcer that fulfilled the
selection criteria, only one ulcer (generally the largest and most clinically significant) was selected as the
index ulcer for the purpose of the study. All data were entered into an electronic case report form (eCRF),
which also incorporated the randomisation tool.
Baseline clinical assessment
Participants
The participants’ age, sex and type and duration of diabetes were recorded, as were details of their
mobility. Mobility was graded on a 4-point scale: (1) able to walk unaided, (2) able to walk with assistance,
(3) chairbound and (4) bedbound. A record was also kept of the type of offloading used to reduce
pressure on the ulcerated area. For the purpose of sensitivity analysis of the primary outcome, types of
offloading were divided into two categories: (1) ‘more effective’, that is, those more likely to achieve
effective pressure relief (i.e. a removable below-knee offloading device or cast or a removable fibreglass
BOX 2 Participant eligibility criteria
Inclusion criteria
l Type 1 or type 2 diabetes mellitus.
l Aged ≥ 18 years.
l An ulcer of the heel (below the malleoli and affecting the skin overlying the calcaneum) of NPUAP/EPUAP
grade 2–4 that has been present for ≥ 2 weeks and that has a cross-sectional area of ≥ 25mm2. If there is
more than one heel ulcer, one – the largest or the most clinically significant – will be selected as the
index ulcer.
l Able and willing to give written informed consent.
Exclusion criteria
l Frailty or disability that would mean participation in the study might have an adverse effect on patient
well-being and mood.
l The need for any offloading device to be non-removable.
l The likelihood of protocol violation because of planned travel.
l Those who withhold consent.
l Active participation in another study of a wound-care product.
l The use of topical negative pressure or application of larvae to the index heel ulcer.
Note: the text of this box is reproduced from the previously published protocol,1 and is used here according to
the terms of the licence granted by BioMed Central Ltd. © Jeffcoate et al.; licensee BioMed Central Ltd. 2014.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under
the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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slipper/whole foot device) and (2) ‘less effective’, that is, those less likely to achieve effective pressure relief
(i.e. being bedbound or immobile, normal footwear, fitted footwear/orthoses, fitted insoles/inserts or a
padded slipper or shoe).
Complications of diabetes were recorded simply as whether or not the patient had any history of
cerebrovascular or cardiovascular disease and whether or not they had known nephropathy or retinopathy.
The health status of the participants was documented using the EuroQol-5 Dimensions three-level version
(EQ-5D-3L),20 the EuroQOL health score and the Cardiff Wound Impact Schedule (CWIS).21 The CWIS is a
condition-specific quality-of-life tool with questions grouped into sections on social life, physical symptoms,
daily living and well-being, generating scores of 0–100 for each section. Higher scores indicate a better quality
of life.
Affected foot
The side and the position of the ulcer on the heel were recorded. The arterial blood flow to the foot was
defined by palpability of pedal pulses (posterior tibial and dorsalis pedis) and ankle brachial pressure index
(ABPI). Neuropathy (loss of protective sensation) was assessed using a 10-g monofilament under the first
metatarsal head, the fifth metatarsal head and under the pulp of the hallux.
Ulcer
The area of the chosen index ulcer was determined using Image J software (National Institutes of Health,
Bethesda, MD, USA)22 from an acetate tracing made using a prespecified procedure. For the purposes of
inclusion and stratification, the area was assessed at baseline by a non-blinded clinical researcher from a
tracing made onto a sterile acetate sheet. These assessments were later checked (after randomisation) by a
single, central, blinded observer who was not otherwise involved in the conduct of the study, and the area
was determined using Image J software. This assessment of the area was taken as the definitive baseline
area for use in data analyses. Images were also taken of acetate tracings of the ulcer (as well as of the
ulcer itself) at each subsequent clinic visit. The non-blinded clinical observer also estimated the granulation
BOX 3 Components of good standard usual care of chronic wounds
1. Provision of any necessary offloading.
2. Debridement:
i. Sharp.
ii. Other as appropriate (excluding the use of larvae).
3. Appropriate dressing products.
4. Appropriate antibiotic therapy.
5. Nutrition and self-care.
6. Optimal glycaemic control.
7. Revascularisation if deemed necessary and possible.
8. Continued close observation.
Note: the text of this box is reproduced from the previously published protocol,1 and is used here according to
the terms of the licence granted by BioMed Central Ltd. © Jeffcoate et al.; licensee BioMed Central Ltd. 2014.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under
the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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percentage of the ulcer base, the amount of exudate and the condition of the surrounding skin. Pain in
the region of the ulcer (if any) was quantified using a 10-cm visual analogue scale (VAS).
Intervention
Both groups received usual care delivered by a specialist service designed for the management of ulcers of
the foot in diabetes mellitus. In addition to usual care, those in the intervention group had a lightweight,
fibreglass cast moulded to their heel. Each cast was lined and flexible at the edges but reinforced over the
ulcerated area and was intended to be thin enough to be worn inside footwear or another offloading
device. It was applied over the primary dressing and a single protective layer of Softban® (BSN Medical,
Hull, UK) or equivalent bandage. The cast was then held in place by bandaging. The choice of primary
dressing and any other secondary dressing was at the discretion of the participating centre. The cast was
removable and was reapplied over the primary dressing with each dressing change until it needed to be
replaced when it was soiled, lost or otherwise unusable. The design of the cast was based on that reported
by the group originally reporting a good outcome with the use of such casts,16 and all researchers involved
in the clinical management of ulcers at each centre were trained by a single specialist podiatrist in how
to make heel casts according to the study specific procedure. Researcher performance was assessed every
6 months by a designated competent researcher, whose own performance was also assessed twice over
the course of the study.
Study conduct
Following randomisation, participants were asked to attend the specialist clinic for review every 2 weeks.
The ulcer was cleaned with local sharp debridement if required. It was then dressed using the primary
dressing of choice of the participant’s usual carer. Participants in the intervention group then had their
heel cast repositioned (a new cast having been made if necessary) and held in place with a bandage as
described above. Any intercurrent infection, deterioration or other clinical problem was treated in
accordance with usual practice.
If the ulcer was thought to be healed, it was checked by an observer who was blind to randomisation
group and it was reviewed after a further 2 and 4 weeks. If the ulcer broke down within 4 weeks, the
person was asked to continue in the study, attending the clinic every 2 weeks. If healing was confirmed
4 weeks after initial healing, the person was asked to attend only the research visits at week 12 (assuming
that this had not already passed) and week 24. If an ulcer was first judged to be healed at week 22 or 24,
the participant remained in the study until healing had or had not been confirmed by a blinded observer
after 4 weeks. A participant’s failure to attend two consecutive fortnightly visits or a total of three visits
during the 24-week follow-up period was regarded as a protocol violation necessitating that person’s
withdrawal from the study. Failure of those in the intervention group to use the heel cast for > 7
consecutive days or for a cumulative total of > 14 days was regarded as a protocol violation, but –
following the protocol amendment of 29 March 2012 (see Protocol amendment) – did not necessitate
their withdrawal from the study.
Withdrawal
Participants were removed from the study if they (1) withdrew consent to participate, (2) lost capacity,
(3) were recruited in error, (4) did not attend the required number of follow-up visits or (5) were lost to
follow-up. Prior to the protocol amendment in March 2012, participants randomised to the intervention arm
were also withdrawn if they violated the protocol with regard to use of the cast (see Protocol amendment).
METHODS
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Objectives
The primary objective was to determine whether or not the use of a heel cast in addition to usual care was
associated with a higher incidence of healing at or before 24 weeks than usual care alone.
Outcomes
Primary outcomes
The primary outcome was healing that was first identified on or before 24 weeks from randomisation.
Healing was defined as epithelialisation maintained for 4 weeks and confirmed by an observer blind
to randomisation group. When confirmed, the date of healing was taken as that on which it was
first observed.
Secondary outcomes
Ulcer-related outcomes
l Time to healing.
l Change in ulcer area (measured from digital images made of acetate tracings with area calculated
using Image J software).
l Secondary infection.
l Major and minor amputation.
l Ulcer recurrence.
l Secondary ulceration on either limb.
Patient-related outcomes
l Local pain (VAS).
l EQ-5D-3L.
l CWIS.
l Hospital admission (including both admissions that were primarily related and admissions that were
unrelated to the heel ulcer).
l Adverse effects.
l Death.
Data on length of hospital stay were not recorded.
Sample size
The expected percentages of healed ulcers at or before 24 weeks in the control group and the treatment
group were 40% and 55%, respectively. With two-sided significance level of 5% (α = 0.05), power = 80%
and estimated non-collection of primary outcome data of 25%, a total of 496 patients to be randomised
was required in order to achieve 186 in each group for the primary analysis.
Randomisation
Randomisation was stratified by ulcer grade (NPUAP/EPUAP grade 2, 3 or 4; see Box 1) and by ulcer area
(25–100 mm2 or > 100 mm2), using randomly permuted blocks of randomly varying size. Randomisation
was undertaken by Nottingham Clinical Trials Unit, using a secure web-based system to ensure allocation
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concealment. This system was embedded within the eCRF, and, once the clinical data were entered at the
time of the randomisation visit, the allocation was revealed immediately to the researcher online.
Blinding
Owing to the nature of the intervention, it was not possible to blind either the participant or the clinical
researcher. However, all of the confirmation assessments of healing and laboratory measures were
undertaken by an observer who was blind to randomisation group. In addition, all images of ulcer tracings
used to document change in ulcer area were measured by a single, central blinded observer.
Statistical analysis
The analysis and reporting of the trial was in accordance with the Consolidated Standards of Reporting
Trials (CONSORT) guidelines.23 Analyses were detailed in a statistical analysis plan (SAP), which was
finalised prior to database lock but after publication of the trial protocol. Participants were analysed
according to their randomised allocation regardless of their adherence to their allocated intervention and
without imputation for missing data for all primary and secondary outcomes [in keeping with the
intention-to-treat (ITT) principle]. All analyses were conducted using Stata® version 13.1 (StataCorp LP,
College Station, TX, USA).
Preliminary analyses
Descriptive statistics of demographic and clinical measures were used to examine the balance between the
randomised arms at baseline.
Primary outcome
Ulcer healing (the primary outcome measure) was assessed independently by two statisticians based on data
recorded at each participant visit by clinical researchers and an observer who was blinded to treatment
allocation. Full details of the assessment of ulcer healing can be found in Appendix 1. A participant met the
criteria for a healed ulcer if, 4 weeks after the clinical researcher and a blinded clinician at the site had initially
judged the ulcer to have healed, the ulcer was judged to have remained healed by both the clinical
researcher and the blinded observer. The time to healing was recorded as the number of days between
randomisation and the date of the visit that the ulcer was first judged healed by the clinical researcher.
The primary analysis compared the proportion of participants with healed ulcers at or before 24 weeks in
the intervention group versus the standard care group. The number and percentage of participants with a
healed ulcer at or before 24 weeks were presented for each group, and relative [odds ratio (OR)] and
absolute (risk difference) measures of effect, along with 95% confidence intervals (CIs) and p-values,
were estimated using multivariable, generalised linear regression models for binary variables, adjusted for
baseline ulcer size and grade as stratification factors.
Sensitivity analyses of the primary outcome
Sensitivity analyses of the primary outcome were performed with additional adjustment for any other
prognostic variables that showed a marked imbalance at baseline. Missing data were imputed using the
multiple imputation by chained equation procedure, implemented using the ‘mi’ command in Stata
version 13.1. The number of imputations was set to 20, which ensured that the number of imputations
was greater than the number of missing data. The imputation model followed recommended practice by
including demographic variables without missing data alongside outcomes with missing data. The ORs for
ulcer healing from the logistic regression analysis in each imputed data set were combined using Rubin’s
rules. In addition to multiple imputation, simple imputation was used assuming that all participants with
missing primary outcome data remained unhealed. The primary analysis was also repeated with the data
restricted to participants who were deemed not to have violated the protocol.
METHODS
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Subgroup analyses of the primary outcome
Prespecified subgroup analyses of the primary outcome were performed according to the following
variables: baseline ulcer area (≤ 100 vs. > 100 mm2), baseline ulcer grade (depth grade 2 vs. grade 3 vs.
grade 4), baseline mobility (immobile vs. mobile), baseline ABPI (< 0.9 vs. 0.9–1.4 vs. > 1.4), neuropathy
(yes vs. no) and age at randomisation (< 70 vs. ≥ 70 years). A further post hoc subgroup analysis was also
performed according to offloading at baseline (‘more effective’ vs. ‘less effective’). These subgroup
analyses were conducted by the inclusion of appropriate interaction terms in the regression model and
were considered to be exploratory.
Secondary outcomes
Time to healing
The time to complete healing of the index ulcer was compared between the two randomised groups using
survival analysis. Kaplan–Meier survival curves were produced for the two groups, and the adjusted hazard
ratio and 95% CI were estimated using a Cox proportional hazards model including stratification factors
(ulcer size and grade). Participants with heel ulcers that were not healed or for which healing data were
not available were treated as censored, and the date of their exit from the trial, their last available
assessment or their 24-week visit, as appropriate, was used to calculate the duration of time for which
they participated in the trial.
Ulcer area
The ulcer area was estimated based on the measurements from digital images of an acetate tracing, or
from the digital images of the ulcer itself if it was not possible to determine the area from the image of
the acetate tracing. The mean ulcer area for those participants who remained unhealed was summarised
at each time point by treatment arm. In a post hoc analysis, the association between ulcer area change
from baseline to 4 weeks and final healing status was investigated using logistic regression. Extreme
outliers, defined as those with a greater than twofold increase in ulcer area at 4 weeks compared with
baseline, were excluded from this analysis. Using interaction terms in the model, we investigated whether
or not any association differed according to baseline ulcer area or treatment arm. No evidence of
interaction was found, and the estimated association is adjusted for baseline area and grade of ulcer and
for treatment arm.
Other ulcer-related secondary outcomes
The binary outcomes of infection, major amputation, minor amputation, revascularisation of the limb with
the target ulcer or a trip or fall leading to hospital admission were derived as outlined in Appendix 2. The
binary secondary outcomes for any hospital admission, a new ulcer on the target foot or a new ulcer on
the contralateral foot were derived as outlined in Appendix 3.
Data are described using the number and percentage of participants with each outcome by treatment arm,
and compared using multivariable logistic regression, adjusted for baseline ulcer area and grade.
EuroQol-5 Dimensions-3 level version and Cardiff Wound Impact Schedule
Cardiff Wound Impact Schedule scores were derived for social life, physical symptoms and daily living and
well-being on a scale of 0–100. Up to 50% of missing items could be imputed for each scale based on the
within-person mean score of observed items in the scale. The experience and stressfulness items for the
social life and physical symptoms and daily living scales were considered separately for this purpose.
The EQ-5D-3L utility score, EQ-5D-3L health status score, CWIS social life score, CWIS physical symptom
and daily living score, CWIS well-being score, CWIS overall quality of life and satisfaction with quality of
life over the past week were summarised by treatment groups at baseline, 12 weeks and 24 weeks. The
scores were analysed using a linear mixed-effects model, with the participant as a random effect and
baseline value of the outcome and the baseline ulcer area and grade as covariates. This model used all of
the observed data and estimated the adjusted between-group difference ‘averaged’ across all follow-up
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occasions, in this case at 12 weeks and 24 weeks. We investigated whether or not any between-group
differences changed over time using interaction terms in the model between treatment arm and time and
found no evidence of any such interactions.
Ulcer-related local pain (visual analogue scale)
Ulcer-related pain for those who remained unhealed at the end of the study was summarised in the two
groups and analysed using analysis of covariance, implemented using multivariable linear regression
adjusting for baseline pain score, ulcer area and ulcer grade. Pain scores at baseline, 4 weeks and 24 weeks
were positively skewed and were log-transformed for analysis, with adjusted ratio of geometric means as
the between-group estimate of effect. Pain at follow-up was also analysed as a binary variable (any pain vs.
no pain) using multivariable logistic regression. Additional post hoc analyses restricted to the subset of
participants who reported any ulcer-related pain at baseline were performed and designed to compare the
difference in pain scores (continuous variable) between groups at 2 weeks and 4 weeks, adjusted for
baseline pain and baseline ulcer area and grade.
Health economic analysis
The health economic evaluation originally set out to estimate the cost-effectiveness of the use of
lightweight heel casts versus usual care by developing a decision-analytic model across a series of time
horizons that reflect the management of patients with diabetic ulcers of the heel. A health economic
analysis plan was constructed in accordance with the trial SAP as follows:
1. Carry out a within-trial analysis of cost-effectiveness (including cost–utility) of the use of lightweight
heel casts versus usual care.
2. Depending on the within-trial results, carry out an analysis of the longer-term cost-effectiveness over
agreed time horizons with a budget impact analysis for 1-year and 5-year periods, which will compare
the costs to the NHS of the use of heel casts plus usual care with usual care alone in the management
of ulcers of the heel in diabetes mellitus.
In accordance with the NICE reference case,24 the perspective adopted was a UK NHS and Personal
Social Services (PSS) one. The primary end point for the economic analysis was an incremental cost per
quality-adjusted life-year (QALY), and the secondary end point was an estimation of incremental cost per
percentage of additional healed ulcers at 24 weeks. Base case results were calculated using a series of
sensitivity analyses, undertaken to assess the degree to which variations in parameter estimates would
affect the relative cost-effectiveness ratios. Bootstrapping was undertaken to address the uncertainty
associated with point estimates of costs and outcomes, and to produce CIs for the incremental
cost-effectiveness ratio (ICER). Cost-effectiveness acceptability curves (CEACs) were generated to give a
range of cost-effectiveness thresholds for decision-makers. A detailed description of the health economics
methods is provided in Appendix 4, including the justification for the health economic analysis being
constrained to a within-trial analysis.
Safety end points
The study population was one that was relatively older and that had a high prevalence of comorbidities,
including renal, cardiac and cerebrovascular diseases. Moreover, ulcers of the foot may worsen, potentially
resulting in hospital admission. Although no specific safety issues were foreseen with the use of the heel
cast, significant events were listed among the secondary outcome measures. Other unexpected ADEs were
recorded and, if considered serious (SADEs), were reported to the sponsor in accordance with the
principles of GCP.
METHODS
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Adverse events
Adverse events were documented only in the period prior the protocol amendment dated 29 March 2012.
Those AEs that were documented were mentioned either spontaneously or in response to questioning. The
clinical researcher assessed the causal relationship of the AE to the use of the fibreglass heel cast (if used).
In addition, AEs were rated according to severity – mild, moderate or severe – using predefined criteria.
Foreseeable adverse events
A number of AEs were likely to occur in the study population. These were recorded as secondary
outcomes and included:
l ulcer-related outcomes
¢ increase in ulcer area
¢ infection
¢ major and minor amputation
¢ recurrence after healing
¢ new ulceration of either limb
l patient-related outcomes
¢ increase in pain
¢ worsening mood or function
¢ hospital admission or death from pre-existing medical conditions.
Adverse device effects
Following the change to the protocol on 29 March 2012, data were collected on ADEs and SADEs. An
ADE was regarded as any untoward and unintended consequence of the use of the device, including any
effect resulting from insufficiencies or inadequacies in the instructions for its use and any effect resulting
from user error or accident. The researcher was required to grade the severity of any ADE as ‘mild’,
‘moderate’ or ‘severe’ and to assess the causal relationship of the ADE to the device as ‘none’, ‘possible’ or
‘probable’ using prespecified criteria. Foreseeable ADEs were those related to worsening of the clinical
state of the ulcer and were reported as secondary outcomes. These included increase in ulcer area,
infection, major and minor amputation, ulcer recurrence and secondary ulceration on either foot. Other
foreseeable patient-related AEs were also recorded as secondary outcomes, including an increase in pain,
worsening mood or function, hospital admission (relating primarily to the heel ulcer) and death from
pre-existing medical conditions.
Serious adverse device effects
These were defined as any ADE that resulted in death, life-threatening illness or injury, hospitalisation or
additional medical or surgical intervention. The causal relationship between the SADE and the use of the
device was documented as ‘none’, ‘possible’ or ‘probable’ using prespecified criteria.
Patient-related AEs that were unrelated were also recorded as secondary outcomes. These included an
increase in pain, worsening mood or function, hospital admission (relating primarily to the heel ulcer) and
death from pre-existing medical conditions.
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Chapter 3 Results
Participant flow
The details of participant flow are shown in Figure 1. From 1915 people who were screened at
participating specialist units and who had diabetes mellitus complicated by heel ulcers, 509 participants
were recruited. Two hundred and fifty-three were randomised to continue with usual care (control), and
256 were randomised to the intervention arm (although the actual use of a heel cast was later recorded
in only 244). A total of 84 participants (16.5%) did not complete the study (44 in the intervention group
and 40 in the control group), but a primary outcome was available for the remaining 425 (212 in the
intervention group and 213 in the control group).
Recruitment
Recruitment started in April 2011 and continued until September 2014. Follow-up was completed in
March 2015. Specialist NHS centres routinely involved in the management of diabetic foot disease were
included progressively during the active phase of the study. The total number of involved centres was 35
(Table 1).
Patients screened
(n = 1915)
Randomised
(n = 509)
Not randomised
(n = 1406)
Allocated to usual wound care +
fibreglass heel cast
(n = 256)
• Received treatment, n = 244
• Receipt of treatment unknown, n = 12
Primary outcome not available
(n = 44)
• Protocol violation, n = 18
   • Eligibility criteria breach, n = 4
   • Failure to wear heel cast, n = 8
   • Missed visits, n = 6
• Withdrawn consent, n = 12
• Loss to follow-up, n = 10
• Other, n = 4
Included in primary analysis
(n = 212)
Allocated to usual wound care
(n = 253)
Primary outcome not available
(n = 40)
• Adverse event/device effect, n = 2
• Protocol violation, n = 10
   • Eligibility criteria breach, n = 3
   • Missed visits, n = 7
• Withdrawn consent, n = 11
• Loss to follow-up, n = 13
• Other, n = 4
Included in primary analysis
(n = 213)
FIGURE 1 Consolidated Standards of Reporting Trials diagram.
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TABLE 1 Trial recruitment by intervention arm and participating site
Site Usual care (n= 253) Intervention (n= 256) Total (n= 509)
Royal Derby Hospital 26 23 49
Nottingham University Hospitals NHS Trust 27 14 41
Torbay Hospital – South Devon Healthcare 20 20 40
Norfolk and Norwich Hospitals NHS Trust 13 18 31
Central Essex Community Services 15 13 28
Royal Cornwall Hospitals NHS Trust 13 12 25
Bradford Teaching Hospitals 12 12 24
Sheffield Teaching Hospitals 11 12 23
Ipswich Hospital NHS Trust 9 11 20
Royal Devon and Exeter Foundation Trust 11 9 20
Royal Berkshire NHS Foundation Trust 7 10 17
NHS Gloucestershire Care Services 7 10 17
Cambridge University Hospitals 5 10 15
City Hospitals Sunderland 7 7 14
Northumbria Healthcare NHS Trust 6 6 12
Salford Royal NHS Foundation Trust 5 7 12
Mid Yorkshire Hospitals 4 7 11
Newcastle upon Tyne Hospitals 9 2 11
Morriston Hospital Swansea NHS Trust 7 4 11
Northampton General Hospital NHS Trust 4 7 11
The Royal Wolverhampton Hospitals 5 5 10
Barnsley Hospital NHS Foundation Trust 2 8 10
Royal Bournemouth and Christchurch Hospitals 6 3 9
South Tees Hospitals NHS Trust 3 4 7
University of Leicester Hospitals 4 3 7
Plymouth Hospitals NHS Trust 3 3 6
St George’s Healthcare NHS Trust 0 5 5
University Hospital of North Staffordshire 2 2 4
New Victoria Hospital – Glasgow and Clyde 0 4 4
The Pennine Acute Hospitals NHS Trust 2 2 4
Yeovil District Hospital NHS Foundation Trust 1 2 3
University Hospitals Coventry and Warwickshire 1 1 2
Greater Glasgow and Clyde Southern General 2 0 2
Royal United Hospital Bath NHS Trust 2 0 2
Imperial College Healthcare NHS Trust 2 0 2
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
Baseline data
Demographics
Baseline details on age, sex, relative mobility, diabetes mellitus type and duration, and the occurrence of
other complications for participating individuals are shown in Table 2. The mean age was as expected for
this population, as was the male preponderance and the relative prevalence of type 1 and type 2 diabetes
mellitus. There were slight imbalances between the intervention and control arms in age, sex and types of
immobility, but the two groups were otherwise well matched.
TABLE 2 Baseline characteristics
Baseline characteristic Usual care (N= 253) Intervention (N= 256) Total (N= 509)
Age at inclusion (years)
Mean (SD) 66.1 (12.6) 68.9 (12.1) 67.5 (12.4)
Median (25th centile, 75th centile) 66.2 (58.1, 75) 70.8 (60.3, 78.1) 68.5 (59.5, 76.8)
Minimum, maximum 25.9, 91.9 28.3, 94.3 25.9, 94.3
Sex
Female 88 (35) 77 (30) 165 (32)
Male 165 (65) 179 (70) 344 (68)
Immobility
No 117 (46) 111 (43) 228 (45)
Yes 136 (54) 145 (57) 281 (55)
Type of immobility
Walking with aid of assistance 92 (36) 112 (44) 204 (40)
Chairbound 43 (17) 31 (12) 74 (14)
Bedbound 1 (1) 2 (1) 3 (1)
Type of diabetes mellitus
Type 1 39 (15) 37 (14) 76 (15)
Type 2 214 (85) 219 (86) 433 (85)
Duration (years)
Mean (SD) 16.9 (11.4) 19.2 (13.0) 18.1 (12.3)
Median (25th centile, 75th centile) 15 (9, 24) 18 (9, 27) 16 (9, 25)
Minimum, maximum 0.5, 61 0.5, 62 0.5, 62
Diabetic complications
Cerebrovascular
Yes 45 (18) 46 (18) 91 (18)
Cardiovascular
Yes 128 (51) 135 (53) 263 (52)
Nephropathy
Yes 89 (35) 90 (35) 179 (35)
Retinopathy
Yes 128 (51) 144 (56) 272 (53)
SD, standard deviation.
Note
All data are n (%) unless otherwise indicated.
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Baseline health status
Baseline health status was mostly well balanced between the intervention and control arms, with the
exception of EQ-5D-3L health score, and the scores overall reflected the impact of chronic ulceration
(Table 3).
Baseline details of the limb and foot
The details of the target ulcer and foot shown in Table 4 demonstrate that the intervention and control arms
were mostly well balanced. The majority had demonstrable loss of sensation using a 10-g monofilament.
The presence of neuropathy (reduced protective sensation) was defined as the inability to detect a 10-g
monofilament at two or three of the three sites tested on the index foot (under the first metatarsal head,
under the fifth metatarsal head and under the hallux pulp), and was documented in 64% of the participants.
Only 34% had both the posterior tibial and dorsalis pedis pulses palpable, and mean ABPI lay in the accepted
normal range of 0.9–1.4 in only 36%, although it should be noted that ABPI was not reported in 30% of the
total population (see Appendix 5).
Baseline details of the ulcer (see Table 4)
Area
The median baseline area of the index ulcer, determined retrospectively by the blinded observer, was
206 mm2 [25th centile, 75th centile: 77 mm2, 649 mm2] in the control group and 275 mm2 (25th centile,
75th centile: 104 mm2, 683 mm2) in the intervention group.
National Pressure Ulcer Advisory Panel/European Pressure Ulcer Advisory Panel
grade (depth)
The distribution of ulcers was identical in the intervention and control groups: grade 2, 32%; grade 3,
62%; and grade 4, 6%.
Pain
Local pain was reported by 78% of participants overall: intervention group, 77%; and control group, 78%.
Wound bed
The base of each ulcer was scored for the granulating percentage (median 40%), the extent of slough
coverage of the ulcer (median 30%) and of necrosis (median 30%), the level of exudate (none, light,
moderate or heavy) and the condition of the surrounding skin (intact, callus, macerated, erythematous,
oedematous or other) and was well balanced between the two arms.
Offloading
The participants used a range of offloading devices, and the proportion using these devices was similar in
the two arms.
Study quality
Baseline ulcer area
Baseline ulcer area used for determining eligibility and for stratified randomisation, and ulcer area later
judged by the central blinded observer, are shown in Table 5. In 24 participants, the ulcer area was
assessed as < 25 mm2 by the blinded observer; categorisation of ulcer size was discrepant for a further
94 participants. As would be expected, the number of discrepancies was approximately the same in
each arm.
Completeness of follow-up at weeks 12 and 24 by randomisation group
Table 6 shows the numbers of participants in either group who completed visits at weeks 12 and 24.
These figures include those who died or were withdrawn as well as those in whom healing had already
RESULTS
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TABLE 3 Baseline health status
Measures of well-being and function Usual care (N= 253) Intervention (N= 256) Total (N= 509)
EQ-5D-3L health score (0–100)
Mean (SD) 50.9 (24.5) 55.4 (23.9) 53.2 (24.3)
Median (25th centile, 75th centile) 50 (40, 70) 55 (40, 73) 50 (40, 70)
Minimum, maximum 0, 100 0, 100 0, 100
n 246 251 497
EQ-5D-3L utility score
Mean (SD) 0.43 (0.35) 0.45 (0.31) 0.44 (0.33)
Median (25th centile, 75th centile) 0.5 (0.1, 0.7) 0.6 (0.2, 0.7) 0.5 (0.2, 0.7)
Minimum, maximum –0.5, 1 –0.5, 1 –0.5, 1
n 241 249 490
CWISa
Social life
Mean (SD) 62.9 (25.6) 62.8 (22.1) 62.9 (23.9)
Median (25th centile, 75th centile) 66.1 (42.9, 84.8) 62.5 (48.2, 80.4) 64.3 (46.4, 80.4)
Minimum, maximum 3.6, 100 0, 100 0, 100
n 244 252 496
Physical symptoms and daily living
Mean (SD) 61.3 (21.1) 61.5 (19.1) 61.4 (20.1)
Median (25th centile, 75th centile) 62.5 (45.8, 79.2) 62.5 (49, 75) 62.5 (46.9, 77.1)
Minimum, maximum 8.3, 100 9.4, 100 8.3, 100
n 245 253 498
Well-being
Mean (SD) 45.9 (20.3) 48.9 (19.2) 47.4 [19.8]
Median (25th centile, 75th centile) 42.9 (32.1, 57.1) 46.4 (35.7, 60.7) 46.4 (32.1, 60.7)
Minimum, maximum 0, 100 3.6, 100 0, 100
n 244 253 497
Overall quality of life during the past week
Mean (SD) 5.8 (2.4) 6.0 (2.3) 5.9 (2.3)
Median (25th centile, 75th centile) 6 (5, 8) 6 (5, 8) 6 (5, 8)
Minimum, maximum 0, 10 0, 10 0, 10
n 243 250 493
Satisfaction with overall quality of life during the past week
Mean (SD) 5.7 (2.8) 5.7 (2.7) 5.7 (2.7)
Median (25th centile, 75th centile) 6 (4, 8) 6 (4, 8) 6 (4, 8)
Minimum, maximum 0, 10 0, 10 0, 10
n 243 251 494
SD, standard deviation.
a CWIS is a condition-specific quality-of-life tool with questions grouped into sections on social life, physical symptoms and
daily living, and well-being with scores of between 0 and 100 derived for each section. Higher scores indicate a better
quality of life. Overall quality of life is also rated on a scale of 0 (worst possible quality of life) to 10 (best possible quality
of life), and satisfaction with overall quality of life is rated on a scale of 0 (not at all satisfied) to 10 (very satisfied).
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TABLE 4 Baseline foot ulcer details
Clinical details
Usual care
(N= 253)
Intervention
(N= 256)
Total
(N= 509)
Target foot
Right 121 (48) 115 (45) 236 (46)
Left 132 (52) 141 (55) 273 (54)
Position of ulcer on heel
Plantar 67 (27) 73 (28) 140 (27)
Tip 111 (44) 107 (42) 218 (43)
Medial 57 (22) 71 (28) 128 (25)
Lateral 66 (26) 57 (22) 123 (24)
Dorsalis pedis palpable
Yes 124 (49) 119 (46) 243 (48)
Posterior tibial palpable
Yes 99 (39) 93 (36) 192 (38)
Dorsalis pedis palpable and posterior tibial palpable 92 (36) 83 (32) 175 (34)
ABPI value
< 0.9 70 (28) 68 (27) 138 (27)
0.9–1.4 88 (35) 95 (37) 183 (36)
> 1.4 16 (6) 20 (8) 36 (7)
ABPI not done 79 (31) 73 (28) 152 (30)
Loss of sensation in the following locations
First metatarsal head alone 3 (1) 3 (1) 6 (1)
Fifth metatarsal head alone 6 (2) 6 (2) 12 (2)
Hallux alone 9 (4) 3 (1) 12 (2)
Sensation lost at ≥ two of the above sites 170 (67) 156 (61) 326 (64)
Area of the wound (as recorded at randomisation)
25–100mm2 94 (37) 94 (37) 188 (37)
> 100mm2 159 (63) 162 (63) 321 (63)
Area of the wound (as measured using images of acetate tracings of ulcer), mm2
Digital image of acetate tracing taken at baseline 253 (100) 256 (100) 509 (100)
Wound area measured 251 (99) 256 (100) 207 (99)
Mean (SD) 470.5 (621.2) 556.4 (737.9) 513.9 (683.3)
Median (25th centile, 75th centile) 206 (77, 649) 275 (104, 683) 245 (87, 677)
Minimum, maximum 6, 4243 8, 5002 6, 5002
1–24mm2 14 (5) 10 (4) 24 (5)
25–100mm2 66 (26) 51 (20) 117 (23)
> 100mm2 171 (68) 195 (76) 366 (72)
Grade of ulcer (using NPUAP/EPUAP criteria)
2 82 (32) 83 (32) 165 (32)
3 156 (62) 158 (62) 314 (62)
4 15 (6) 15 (6) 30 (6)
RESULTS
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TABLE 4 Baseline foot ulcer details (continued )
Clinical details
Usual care
(N= 253)
Intervention
(N= 256)
Total
(N= 509)
Local pain VAS (mm)
No pain 56 (22) 57 (22) 113 (22)
With pain 195 (78) 197 (77) 392 (78)
Mean (SD) 32.2 (30.2) 32.9 (28.5) 32.5 (29.3)
Median (25th centile, 75th centile) 24 (2, 56) 28 (5, 56) 26 (4, 56)
Minimum, maximum 0, 100 0, 100 0, 100
n 251 254 505
Wound bed
Granulating (%)
Mean (SD) 46.8 (42.1) 44.7 (40.4) 45.8 (41.2)
Median (25th centile, 75th centile) 40 (0, 97) 40 (0, 90) 40 (0, 90)
Minimum, maximum 0, 100 0, 100 0, 100
n 253 256 509
Slough (%)
Mean (SD) 40.5 (40.3) 38.7 (38.1) 39.6 (39.2)
Median (25th centile, 75th centile) 40 (0, 97) 27.5 (0, 80) 30 (0, 80)
Minimum, maximum 0, 100 0, 100 0, 100
n 253 256 509
Necrosis (%)
Mean (SD) 10.6 (27.8) 15.6 (32.6) 13.1 (39.2)
Median (25th centile, 75th centile) 0 (0, 0) 0 (0, 0) 30 (0, 80)
Minimum, maximum 0, 100 0, 100 0, 100
n 253 256 509
Exudate levels
None 19 (7) 22 (9) 41 (8)
Light 112 (44) 114 (44) 226 (44)
Moderate 99 (39) 102 (40) 201 (39)
Heavy 23 (9) 18 (7) 41 (8)
Condition of the surrounding skin
Healthy intact 85 (34) 88 (34) 173 (34)
Callus 138 (54) 139 (54) 277 (54)
Macerated 89 (35) 87 (34) 176 (35)
Erythematous 33 (13) 28 (11) 61 (12)
Oedematous 36 (14) 20 (8) 56 (11)
Other 20 (8) 22 (9) 42 (8)
continued
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been confirmed. Completeness of data is also shown in Table 6 for participants whose ulcer did not heal
or for whom primary healing data are missing. The proportion attending the visit at week 24 was similar in
the two groups.
Baseline characteristics according to collection of primary outcome data
The primary outcome was collected for a total of 425 (83%) randomised participants. Tables 7–9 suggest
that the baseline characteristics of participants who did and did not provide primary outcome data did not
differ between the treatment arms.
Adherence to wearing the heel cast (in those randomised to the intervention group)
The median percentage of expected time that the heel cast was worn in each case was 100% (Table 10).
Reported mean adherence to wearing the heel casts was higher among those with confirmed ulcer healing.
Protocol violations
The numbers of protocol violations leading to failure to complete the study are given in the CONSORT
diagram (see Figure 1). The details of all protocol violations are listed in Appendix 6.
TABLE 4 Baseline foot ulcer details (continued )
Clinical details
Usual care
(N= 253)
Intervention
(N= 256)
Total
(N= 509)
Type of offloading used
Bedbound or immobile 13 (5) 13 (5) 26 (5)
Normal footwear 57 (22) 57 (22) 114 (22)
Fitted footwear/orthoses 41 (16) 36 (14) 77 (15)
Fitted insoles/inserts 16 (6) 8 (3) 24 (5)
Removable offloading device or cast 57 (22) 53 (21) 110 (22)
Removable fibreglass slipper/whole foot device 6 (2) 26 (10) 32 (6)
Padded slipper or shoe 93 (37) 86 (34) 179 (35)
SD, standard deviation.
Note
All data are n (%) unless otherwise indicated.
TABLE 5 Ulcer size used in randomisation and size measured using images of acetate tracings of the ulcer
Size of heel ulcer based on measurements using images
of acetate tracings of ulcer by blinded observer
Heel ulcer size selected at randomisation
Usual care Intervention
25–100mm2 > 100mm2 25–100mm2 > 100mm2
1–24mm2 14 0 10 0
25–100mm2 53 13 40 11
> 100mm2 26 145 44 151
RESULTS
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Withdrawals
The total withdrawals are given in the CONSORT diagram (see Figure 1). The detailed reasons for
withdrawal are listed in Appendix 7.
TABLE 6 Completeness of week 12 and week 24 follow-up visits by group (compulsory visits)
Follow-up visit Usual care (N= 253) Intervention (N= 256) Total (N= 509)
Week 12 visit completed, n (%) 211 (83) 214 (84) 425 (83)
Weeks from randomisation to week 12 visit
Median (25th centile, 75th centile) 12 (12, 12.4) 12 (12, 12.3) 12 (12, 12.3)
Minimum, maximum 11, 20.4 10, 18.0 10, 20.4
Week 24 visit completed, n (%) 198 (78) 203 (79) 401 (79)
Weeks from randomisation to week 24 visit
Median (25th centile, 75th centile) 24 (24, 25) 24 (24, 24.7) 24 (24, 25)
Minimum, maximum 20, 38.9 18, 38.3 18, 38.9
Completeness of data for participants who did not heal or for whom primary healing data are missinga
Number of visits completed
≤ 10 visits attended 64 (37) 62 (38) 126 (38)
11 visits attended 9 (5) 11 (7) 20 (6)
12 visits attended 37 (21) 21 (13) 58 (17)
All 13 visits attended 63 (36) 68 (42) 131 (39)
Median (25th centile, 75th centile) 12 (7, 13) 12 (6, 13) 12 (6, 13)
Minimum, maximum 1, 13 1, 13 1, 13
Week 24 visit completed, n (%) 124 (72) 114 (70) 238 (71)
Local pain VAS completed 107 (62) 92 (57) 199 (59)
Digital image of acetate of trace of wound
Taken at week 24 92 (53) 84 (52) 176 (52)
Wound area measured 89 (51) 80 (49) 169 (50)
Digital images of wound
Taken at week 24 104 (60) 92 (57) 196 (58)
Number of images in which the wound area is measurable
0 15 (9) 19 (12) 34 (10)
1 4 (2) 3 (2) 7 (2)
2 154 (89) 140 (86) 294 (88)
SD, standard deviation.
a Percentages were calculated using the number of participants who did not heal or when primary healing data is missing
as the denominator.
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TABLE 7 Baseline characteristics according to availability of primary outcome data and group
Baseline characteristics
Usual care (N= 253) Intervention (N= 256)
Primary outcome
data available
(n= 213)
Primary outcome
not known
(n= 40)
Primary outcome
data available
(n= 212)
Primary
outcome not
known (n= 44)
Age at inclusion (years)
Mean (SD) 65.4 (12.3) 66.8 (13.8) 67.8 (11.6) 71.3 (14.5)
Median (25th centile, 75th centile) 66 (58, 74) 69.5 (55, 76.5) 68.5 (60, 77) 76 (61.5, 80)
Minimum, maximum 25, 91 38, 91 39, 94 28, 90
Sex
Female 70 (33) 18 (45) 63 (30) 14 (32)
Male 143 (67) 22 (55) 149 (70) 30 (68)
Immobility
No 98 (46) 19 (47) 98 (46) 13 (29)
Yes 115 (54) 21 (53) 114 (54) 31 (71)
Type of immobility
Walking with aid of assistance 78 (37) 14 (35) 89 (42) 23 (52)
Chairbound 36 (17) 7 (17) 23 (11) 8 (18)
Bedbound 1 (1) 0 2 (1) 0
Diabetes mellitus
Type of diabetes mellitus
Type 1 32 (15) 7 (17) 30 (14) 7 (16)
Type 2 181 (85) 33 (83) 182 (86) 37 (84)
Duration (years)
Mean (SD) 17.0 (11.1) 16.7 (13.0) 18.7 (12.6) 21.8 (14.7)
Median (25th centile, 75th centile) 15 (9, 25) 12.5 (8, 22) 17 (9, 26.5) 20 (11.5, 27.5)
Minimum, maximum 0.5, 61 1, 61 0.5, 62 0.5, 61
Diabetic complications
Cerebrovascular
Yes 39 (18) 6 (15) 38 (18) 8 (18)
Cardiovascular
Yes 108 (51) 20 (50) 112 (53) 23 (52)
Nephropathy
Yes 76 (36) 13 (32) 75 (35) 15 (34)
Retinopathy
Yes 112 (53) 16 (40) 125 (59) 19 (43)
SD, standard deviation.
Note
All data are n (%) unless otherwise indicated.
RESULTS
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TABLE 8 Baseline health status according to availability of primary outcome data and group
Measures of well-being and
function
Usual care (N= 253) Intervention (N= 256)
Primary outcome
data available
(n= 213)
Primary outcome
not known
(n= 40)
Primary outcome
data available
(n= 212)
Primary
outcome not
known (n= 44)
EQ-5D-3L health score (0–100)
Mean (SD) 51.7 (24.9) 46.9 (21.9) 55.5 (24.5) 54.8 (20.8)
Median (25th centile,
75th centile)
50 (40, 70) 49.5 (30, 60) 56 (40, 75) 50 (41, 69)
Minimum, maximum 0, 100 4, 94 0, 100 1, 97
n 208 38 207 44
EQ-5D-3L utility score
Mean (SD) 0.4 (0.3) 0.5 (0.4) 0.4 (0.3) 0.4 (0.3)
Median (25th centile,
75th centile)
0.5 (0.1, 0.7) 0.5 (0.1, 0.7) 0.6 (0.2, 0.7) 0.6 (0.3, 0.6)
Minimum, maximum –0.3, 1 –0.5, 0.9 –0.5, 1 –0.4, 0.8
n 203 38 205 44
CWIS social life
Mean (SD) 63.6 (25.5) 59.3 (26.2) 61.9 (22.4) 67.5 (20.6)
Median (25th centile,
75th centile)
66.1 (44.6, 85.7) 59 (35.7, 78.6) 60.7 (46.4, 78.6) 67.9 (42.2, 78.6)
Minimum, maximum 3.6, 100 16.1, 100 0, 100 21.4, 100
n 206 38 208 44
Physical symptoms and daily living
Mean (SD) 61.6 (21.1) 59.6 (21.5) 61.9 (18.7) 59.6 (20.6)
Median (25th centile,
75th centile)
62.5 (46.9, 80.2) 62.5 (38.5, 78.1) 62.5 (51, 74) 62.5 (42.2, 78.6)
Minimum, maximum 8.3, 100 20.8, 100 9.4, 100 16.7, 91.7
n 207 38 209 44
Well-being
Mean (SD) 46.1 (20.7) 44.5 (18.4) 49.3 (19.3) 46.7 (18.8)
Median (25th centile,
75th centile)
42.9 (32.1, 57.1) 46.4 (32.1, 57.1) 50 (35.7, 60.7) 41.1 (32.1, 62.5)
Minimum, maximum 0, 100 3.6, 82.1 7.1, 100 3.6, 89.3
n 205 39 209 44
Overall quality of life during the past week
Mean (SD) 5.9 (2.4) 5.4 (2.1) 6.0 (2.3) 6.1 (2.1)
Median (25th centile,
75th centile)
6 (5, 8) 5 (4, 7) 6 (5, 8) 6 (5, 8)
Minimum, maximum 0, 10 0, 10 0, 10 0, 10
n 205 38 208 42
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TABLE 8 Baseline health status according to availability of primary outcome data and group (continued )
Measures of well-being and
function
Usual care (N= 253) Intervention (N= 256)
Primary outcome
data available
(n= 213)
Primary outcome
not known
(n= 40)
Primary outcome
data available
(n= 212)
Primary
outcome not
known (n= 44)
Satisfaction with overall quality of life during the past week
Mean (SD) 6.0 (2.8) 4.7 (2.7) 5.6 (2.7) 6.3 (2.7)
Median (25th centile,
75th centile)
6 (4, 8) 5 (3, 6) 6 (4, 8) 7 (5, 8)
Minimum, maximum 0, 10 0, 10 0, 10 0, 10
n 205 38 208 43
SD, standard deviation.
TABLE 9 Baseline foot ulcer details according to availability of primary outcome data and group
Baseline foot ulcer details
Usual care (N= 253) Intervention (N= 256)
Primary outcome
data available
(n= 213)
Primary outcome
not known
(n= 40)
Primary outcome
data available
(n= 212)
Primary
outcome not
known (n= 44)
Target foot
Right 107 (50) 14 (35) 98 (46) 17 (39)
Left 106 (50) 26 (65) 114 (54) 27 (61)
Position of ulcer on heel
Plantar 61 (29) 6 (15) 62 (29) 11 (25)
Tip 91 (43) 20 (50) 85 (40) 22 (50)
Medial 46 (22) 11 (28) 62 (29) 9 (20)
Lateral 54 (25) 12 (30) 44 (21) 13 (29)
Dorsalis pedis palpable
Yes 103 (48) 21 (52) 100 (57) 19 (43)
Posterior tibial palpable
Yes 82 (35) 17 (42) 79 (37) 14 (32)
Dorsalis pedis palpable and posterior tibial palpable
Yes 75 (35) 17 (42) 70 (33) 13 (29)
ABPI value
< 0.9 52 (24) 18 (45) 59 (28) 9 (20)
0.9–1.4 78 (37) 10 (25) 78 (37) 17 (39)
> 1.4 14 (7) 2 (5) 15 (7) 5 (11)
ABPI not done 69 (32) 10 (25) 60 (28) 13 (29)
Loss of sensation in the following locations
First metatarsal head alone 2 (1) 1 (2) 3 (1) 0
Fifth metatarsal head alone 4 (2) 2 (5) 4 (2) 2 (4)
Hallux alone 8 (4) 1 (2) 1 (1) 0
Sensation lost at two or more of
the above sites
147 (69) 23 (57) 128 (60) 28 (64)
Area of the wound (as recorded at randomisation)
25–100mm2 73 (34) 21 (52) 74 (35) 20 (45)
> 100mm2 140 (66) 19 (47) 138 (65) 24 (54)
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TABLE 9 Baseline foot ulcer details according to availability of primary outcome data and group (continued )
Baseline foot ulcer details
Usual care (N= 253) Intervention (N= 256)
Primary outcome
data available
(n= 213)
Primary outcome
not known
(n= 40)
Primary outcome
data available
(n= 212)
Primary
outcome not
known (n= 44)
Area of the wound (mm2) (as measured using images of acetate tracings of ulcer)
Digital image of acetate tracing
taken at baseline
213 (100) 40 (100) 212 (100) 44 (100)
Wound area measured 213 (100) 38 (95) 212 (100) 44 (100)
Mean (SD) 480.6 (601.1) 415.2 (730.3) 542.6 (701.6) 624.0 (901.4)
Median (25th centile,
75th centile)
220 (80, 663) 170.5 (46, 531) 275.5 (113, 674) 283.5 (83.5, 809)
Minimum, maximum 6, 4007 9, 4243 8, 5002 15, 4553
1–24mm2 10 (5) 4 (10) 9 (4) 1 (2)
25–100mm2 55 (26) 11 (27) 39 (18) 12 (27)
> 100mm2 148 (69) 23 (57) 164 (77) 31 (71)
Grade of ulcer (using NPUAP/EPUAP criteria)
2 69 (32) 14 (35) 68 (32) 15 (34)
3 131 (61) 25 (62) 130 (61) 28 (64)
4 14 (7) 1 (2) 14 (7) 1 (2)
Local pain VAS (mm)
Mean (SD) 30.4 (29.7) 41.9 (31.9) 31.9 (28.6) 37.7 (27.6)
Median (25th centile,
75th centile)
22 (1.5, 55) 44 (9, 75) 26.5 (4, 53) 35 (16, 59.5)
Minimum, maximum 0, 100 0, 100 0, 100 0, 90
n 212 40 210 44
Wound bed
Granulating (%)
Mean (SD) 48 (42) 42 (43) 44 (41) 50 (38)
Median (25th centile,
75th centile)
40 (1, 95) 25 (0, 100) 35 (0, 87) 50 (13, 95)
Minimum, maximum 0, 100 0, 100 0, 100 0, 100
n 213 40 212 44
Slough (%)
Mean (SD) 41 (40) 38 (41) 39 (38) 38 (36)
Median (25th centile,
75th centile)
30 (0, 80) 20 (0, 85) 20 (0, 80) 30 (0, 72)
Minimum, maximum 0, 100 0, 100 0, 100 0, 100
n 213 40 212 44
Necrosis (%)
Mean (SD) 9 (26) 17 (35) 16 (33) 12 (30)
Median (25th centile,
75th centile)
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Minimum, maximum 0, 100 0, 100 0, 100 0, 100
n 213 40 212 44
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Primary outcome
Ninety-four out of 212 (44%) ulcers healed in the intervention group, compared with 80 out of 213 (37%)
in the usual care group (OR 1.42, 95% CI 0.95 to 2.14; p = 0.088). The risk difference was 8% (95% CI
–1% to 17%; p = 0.087) (Table 11). These data suggest that any effect of the intervention is less than that
used in designing the trial (risk difference 15%). The possibility of no effect or even a very small harmful
effect cannot be ruled out using conventional 95% CIs. Further adjustment for sex and baseline mobility
type (due to baseline imbalance) had minimal impact and resulted in OR 1.42 (95% CI 0.94 to 2.15).
Imputation of missing primary outcome data
Simple and multiple imputation of missing primary outcome data slightly reduced the magnitude of the
effect (Table 12).
TABLE 9 Baseline foot ulcer details according to availability of primary outcome data and group (continued )
Baseline foot ulcer details
Usual care (N= 253) Intervention (N= 256)
Primary outcome
data available
(n= 213)
Primary outcome
not known
(n= 40)
Primary outcome
data available
(n= 212)
Primary
outcome not
known (n= 44)
Exudate levels
None 18 (8) 1 (2) 16 (7) 6 (14)
Light 90 (42) 22 (55) 96 (45) 18 (41)
Moderate 83 (39) 16 (40) 85 (40) 17 (39)
Heavy 22 (10) 1 (2) 15 (7) 3 (7)
Condition of the surrounding skin
Health intact 74 (35) 11 (27) 73 (34) 15 (34)
Callus 114 (53) 24 (60) 116 (55) 23 (52)
Macerated 76 (36) 13 (32) 72 (34) 15 (34)
Erythematous 26 (12) 7 (17) 25 (12) 3 (7)
Oedematous 34 (16) 2 (5) 16 (7) 4 (9)
Other 16 (7) 4 (10) 16 (7) 6 (14)
Type of offloading used
Bedbound or immobile 11 (5) 2 (5) 11 (5) 2 (4)
Normal footwear 43 (20) 14 (35) 50 (24) 7 (16)
Fitted footwear/orthoses 36 (17) 5 (12) 32 (15) 4 (9)
Fitted insoles/inserts 15 (7) 1 (2) 7 (3) 1 (2)
Removable below-knee offloading
device or cast
47 (22) 10 (25) 40 (19) 13 (29)
Removable fibreglass
slipper/whole foot device
6 (3) 0 20 (9) 6 (14)
Padded slipper or shoe 80 (38) 13 (32) 69 (32) 17 (39)
SD, standard deviation.
Note
All data are n (%) unless otherwise indicated.
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TABLE 10 Adherence to wearing the heel cast
Measures of adherence Intervention (N= 256)
Participant attended at least one follow-up visit, n (%) 244 (95)
Percentage of time that heel cast was worn during study
Mean (SD) 90 (23)
Median (25th centile, 75th centile) 100 (90, 100)
Minimum, maximum 0, 100
n 244
Heel cast not worn for 7 consecutive days or > 14 days in total, n (%) 44 (17)
Percentage of time that the heel cast was worn for different participant groups distinguished by clinical
outcome
With confirmed ulcer healing
100%, n 77 (82%)
< 100%, n 17 (18%)
Mean (SD) 97% (8%)
Median (25th centile, 75th centile) 100% (100%, 100%)
Minimum, maximum 40%, 100%
n 94
Who did not heal and attended the week 24 visit
100%, n 60 (58%)
< 100%, n 43 (42%)
Mean (SD) 87% (27%)
Median (25th centile, 75th centile) 100% (90%, 100%)
Minimum, maximum 0, 100%
n 103
Who did not heal and did not attend week 24 visit
100%, n 6 (54%)
< 100%, n 5 (46%)
Mean (SD) 79% (34%)
Median (25th centile, 75th centile) 100% (90%, 100%)
Minimum, maximum 0, 100%
n 11
With healing status unavailable
100%, n 16 (45%)
< 100%, n 20 (55%)
Mean (SD) 85% (27%)
Median (25th centile, 75th centile) 100% (80%, 100%)
Minimum, maximum 0, 100%
n 36
SD, standard deviation.
Notes
Heel cast was expected to be worn continuously during the time that the ulcer remained unhealed.
Heel cast wearing information was not available for n= 12 participants, as they did not proceed to any follow-up visit
after baseline.
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Subgroup analysis of the primary outcome
Although the subgroup-specific ORs suggest a greater intervention effect among participants with larger
ulcers, there was no strong statistical evidence of a differential treatment effect for this or any of the other
subgroup analyses (Table 13).
Per-protocol analysis
Of the 425 participants with primary outcome data, a total of 420 (99%, 210 in each treatment arm) were
deemed to have completed the study as per protocol (PP). Comparison of the primary outcome in the PP
sample was therefore very similar to that from the primary analysis (adjusted OR 1.41, 95% CI 0.94 to 2.12)
(Table 14).
Secondary outcomes
Time to healing
The Kaplan–Meier curve for time to healing in the two groups is illustrated in Figure 2. The Cox regression
analysis suggested some evidence that participants in the intervention arm healed faster than those in the
usual care arm (adjusted hazard ratio 1.30, 95% CI 0.97 to 1.75; p = 0.083).
Change in ulcer area
The mean ulcer area in each of the two groups is plotted against time in Figure 3. The mean change from
baseline is shown in Figure 4. It should be noted that these plots include all participants who remained
unhealed at each time point.
TABLE 11 Healing within 24 weeks
Percentage healed
within 24 weeks
Usual care
(n= 253)
Intervention
(n= 256)
OR for ulcer healing
(95% CI); p-value
Risk difference (%) for
ulcer healing (95% CI);
p-value
Primary outcome data
available
213 212 1.42 (0.95 to 2.14); p= 0.088 8 (–1 to 17); p = 0.087
Unhealed 133 (62%) 118 (56%)
Healed 80 (38%) 94 (44%)
Note
The OR and risk difference are adjusted for stratification factors used in the randomisation: baseline ulcer size and grade.
TABLE 12 Imputation of missing healing data
Arm Percentage healed (%) OR adjusted for stratification factorsa (95% CI)
Using multiple imputation assuming missing data are missing at random
Usual care 38 –
Intervention 43 1.31 (0.89 to 1.92)
Using simple imputation assuming that all participants with missing data remain unhealed
Usual care 32 –
Intervention 37 1.35 (0.93 to 1.98)
a Adjusted for ulcer size and grade.
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TABLE 13 Subgroup analysis for primary outcome (healing within 24 weeks)
Baseline detail
Usual care
(n= 213)
Intervention
(n= 212)
Subgroup-specific
crude OR (95%CI)
Adjusted interaction
effect (95% CI)a
p-value (for
interaction)
Baseline ulcer area
≤ 100mm2
Unhealed 32 20 0.86 (0.50 to 1.47)
Healed 33 28 1.11 (0.45 to 2.72) 0.817
> 100mm2
Unhealed 101 98 1.45 (0.91 to 2.31)
Healed 47 66
Baseline ulcer grade
Grade 2
Unhealed 36 30 1.42 (0.72 to 2.80)
Healed 32 38
Grade 3
0.97 (0.46 to 2.03) 0.939
Unhealed 86 78 1.27 (0.77 to 2.11)
Healed 45 52
Grade 4
Unhealed 11 10 1.47 (0.26 to 8.23)
Healed 3 4
Baseline mobility status
Mobile
Unhealed 57 54 1.13 (0.64 to 1.99)
Healed 41 44 1.00 (0.44 to 2.27) 0.999
Immobile
Unhealed 76 64 1.52 (0.89 to 2.60)
Healed 39 50
Baseline ABPI
< 0.9
Unhealed 32 36 1.02 (0.47 to 2.20)
Healed 20 23
0.9–1.4 0.90 (0.41 to 1.98) 0.800
Unhealed 46 40 1.36 (0.72 to 2.57)
Healed 32 38
> 1.4
Unhealed 9 10 0.90 (0.19 to 4.16)
Healed 5 5
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Ulcer recurrence after healing
Early recurrence may reflect the quality of healing. The incidence of recurrence was assessed in ulcers that
healed at week 18 or earlier. This cut-off point was selected because an ulcer that recurs within 4 weeks
would have been defined as unhealed, and a minimum follow-up of 6 weeks was therefore needed to
assess recurrence. Seventy-six ulcers (30% of 256) healed in the intervention group by 18 weeks and
recurrence was recorded in 5 (7%) by 24 weeks. In the control arm, 68 (27% of 253) ulcers healed by
18 weeks and recurrence was recorded in 3 (4%) by 24 weeks (Table 15).
TABLE 13 Subgroup analysis for primary outcome (healing within 24 weeks) (continued )
Baseline detail
Usual care
(n= 213)
Intervention
(n= 212)
Subgroup-specific
crude OR (95%CI)
Adjusted interaction
effect (95% CI)a
p-value (for
interaction)
Baseline nephropathy
No
Unhealed 77 73 1.12 (0.70 to 1.81)
Healed 60 64 1.60 (0.66 to 3.85) 0.293
Yes
Unhealed 56 45 1.87 (0.94 to 3.72)
Healed 20 30
Baseline age (years)
< 70
Unhealed 81 60 1.32 (0.79 to 2.21)
Healed 51 50 0.97 (0.42 to 2.22) 0.945
≥ 70
Unhealed 52 58 1.36 (0.75 to 2.48)
Healed 29 44
Baseline offloading
‘More effective’
Unhealed 34 30 1.79 (0.84 to 3.81)
Healed 19 30 1.26 (0.50 to 3.18) 0.621
‘Less effective’
Unhealed 99 88 1.18 (0.75 to 1.86)
Healed 61 64
a Adjusted by baseline ulcer grade and ulcer size.
TABLE 14 Healing within 24 weeks (PP population)
Percentage healed within
24 weeks Usual care (n= 210) Intervention (n= 210)
OR for ulcer healing (95% CI);
p-value
Primary outcome data available 210 210 1.41 (0.94 to 2.12); p= 0.100
Unhealed 130 116
Healed 80 (38%) 94 (45%)
Five participants were excluded from this analysis as they were deemed non-adherent to the trial treatment procedure.
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Health status at weeks 12 and 24
Health status was determined using both the EQ-5D-3L and the CWIS. All measures showed a tendency to
increase between baseline and 12 weeks, indicating an improvement in health status. CWIS measures
increased further at 24 weeks (Table 16). There was evidence of a difference in mean CWIS well-being
score between the intervention and control groups, but there was no evidence of any other differences
between the groups.
Other ulcer-related secondary outcomes
There was some evidence of increased risk of a new ulcer on the contralateral foot in the intervention
group [intervention (17%) vs. control (11%): OR 1.65, 95% CI 0.98 to 2.80; p = 0.061], but no evidence
of any difference for any of the other ulcer-related secondary outcomes (Table 17).
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FIGURE 2 Kaplan–Meier plot of time to healing.
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FIGURE 3 Mean (95% CI) ulcer area over time for unhealed ulcers.
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TABLE 15 Ulcer recurrence with confirmed healing
Number of participants Usual care (N= 253) Intervention (N= 256)
Number of participants confirmed healed 80 94
Number of participants with healing at week 18 or earlier 68 76
Ulcer recurrence, n (%)
Yes 3 (4) 5 (7)
No 57 (84) 66 (87)
Not known 8 (12) 5 (6)
TABLE 16 Health status at weeks 12 and 24 by group
Measures of well-being and function
Baseline
mean (SD)
12 weeks
mean (SD)
24 weeks
mean (SD)
Adjusted difference
in mean (95% CI) p-value
EQ-5D-3L utility score
Usual care 0.43 (0.35) 0.49 (0.34) 0.54 (0.31) – 0.438
Intervention 0.45 (0.31) 0.50 (0.32) 0.52 (0.35) 0.02 (–0.03 to 0.07)
EQ-5D-3L health score (0–100)
Usual care 50.9 (24.5) 57.9 (26.9) 57.4 (26.8) – 0.175
Intervention 55.4 (23.9) 58.6 (24.7) 57.9 (27.9) 2.4 (–1.1 to 5.8)
CWIS social life score
Usual care 62.9 (25.6) 67.3 (24.7) 72.5 (25.2) – 0.820
Intervention 62.8 (22.1) 68.6 (24.1) 69.6 (23.9) 0.4 (–3.2 to 4.0)
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TABLE 16 Health status at weeks 12 and 24 by group (continued )
Measures of well-being and function
Baseline
mean (SD)
12 weeks
mean (SD)
24 weeks
mean (SD)
Adjusted difference
in mean (95% CI) p-value
CWIS physical symptoms and daily living score
Usual care 61.3 (21.1) 65.6 (21.7) 71.3 (21.6) – 0.385
Intervention 61.5 (19.1) 67.8 (20.2) 72.0 (19.9) 1.6 (–1.4 to 4.7)
CWIS well-being score
Usual care 45.9 (20.3) 50.5 (19.3) 57.0 (20.0) – 0.008
Intervention 48.9 (19.2) 56.6 (21.6) 58.9 (20.8) 4.0 (1.1 to 7.0)
CWIS overall quality of life during the past week
Usual care 5.8 (2.4) 6.1 (2.4) 6.3 (2.4) – 0.294
Intervention 6.0 (2.4) 6.1 (2.3) 6.5 (2.4) 0.2 (–0.2 to 0.5)
CWIS satisfaction with overall quality of life during the past week
Usual care 5.7 (2.8) 5.9 (2.7) 6.2 (2.8) – 0.323
Intervention 5.7 (2.7) 6.1 (2.8) 6.4 (2.7) 0.2 (–0.2 to 0.6)
SD, standard deviation.
Notes
CWIS is a condition-specific quality-of-life tool with questions grouped into sections on social life, physical symptoms and
daily living, and well-being, with scores of between 0 and 100 derived for each section. Higher scores indicate a better
quality of life. Overall quality of life is also rated on a scale of 0 (worst possible quality of life) to 10 (best possible quality of
life), and satisfaction with overall quality of life is rated on a scale of 0 (not at all satisfied) to 10 (very satisfied).
TABLE 17 Ulcer-related secondary outcomes during the study
Secondary outcome
Usual care
(N= 245a)
Intervention
(N= 244a) OR (95% CI) p-value
Minor amputation on limb with target ulcer
Number of participants (%) 4 (2) 6 (2) 1.63 (0.45 to 5.90) 0.453
Major amputation on limb with target ulcer
Number of participants (%) 8 (3) 8 (3) 0.93 (0.34 to 2.57) 0.887
Infection on limb with target ulcer
Number of participants (%) 93 (38) 97 (40) 0.99 (0.67 to1.46) 0.978
Total number of visits at which infection reported
(total number of visits asked)
269 (2156) 235 (2167)
Hospital admission
Number of participants (%) 86 (35) 96 (39) 1.18 (0.81 to 1.71) 0.379
Total number of visits at which hospital
admission reported (total number of visits asked)
141 (2156) 151 (2167)
Trip or fall on the limb with the target ulcer leading to a hospital admission
Number of participants (%) 2 (1) 5 (2) 2.60 (0.49 to 13.7) 0.261
Total number of visits resulting from a trip or fall
reported (total number of visits asked)
2 (1822) 7 (1920)
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Ulcer-related pain
There was no evidence of any between-group differences at 4 or 24 weeks in the proportion of
participants who reported pain or in mean pain scores (Table 18). When the population was restricted to
those participants reporting pain at baseline, there was no evidence of any differences between the
intervention and control groups in pain score at baseline or in the reduction of pain between baseline and
either 2 or 4 weeks (Table 19).
Death
Thirteen participants in the usual care group (5%) and 10 participants in the intervention group (4%) died
before the week 24 visit.
Ancillary analyses
Association between change in ulcer area at 4 weeks and healing by 24 weeks
The median per cent reduction in area at 4 weeks was 53% [interquartile range (IQR) –75% to –34%] in
those that went on to heal by 24 weeks, compared with 24% (IQR –48% to 2%) in those that remained
unhealed (adjusted OR = 1.02, 95% CI 1.01 to 1.03; p < 0.001) (Table 20).There was no evidence that
this association differed according to ulcer area at baseline (interaction OR = 1.00, 95% CI 0.99 to 1.01;
p = 0.445) or treatment arm (interaction OR = 0.99, 95% CI 0.97 to 1.00; p = 0.205). Receiver operating
characteristic (ROC) analysis gave an area under the curve (AUC) of 0.78. There was no clear threshold
of change in ulcer area at 4 weeks that reliably differentiated between participants who healed and
participants who remained unhealed at 24 weeks.
TABLE 17 Ulcer-related secondary outcomes during the study (continued )
Secondary outcome
Usual care
(N= 245a)
Intervention
(N= 244a) OR (95% CI) p-value
New ulcer on target foot
Number of participants (%) 55 (22) 57 (23) 1.08 (0.71 to 1.65) 0.719
Total number of visits at which new ulcer
reported (total number of visits asked)
79 (2156) 79 (2167)
New ulcer on contralateral foot
Number of participants (%) 27 (11) 41 (17) 1.65 (0.98 to 2.80) 0.061
Total number of visits at which new ulcer
reported (total number of visits asked)
33 (2156) 54 (2167)
Revascularisation on limb with target ulcer
Number of participants 21 (9) 28 (11) 1.36 (0.75 to 2.48) 0.313
Total number of visits at which revascularisation
reported (total number of visits asked)
25 (2152) 34 (2164)
a n= 489 participants reported any of the outcomes.
Note
Ulcer-related secondary outcomes were completed until ulcer healing.
Revascularisation was only collected after amendment on 29 March 2017.
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Serious adverse events, adverse events, serious adverse device
effects and adverse device effects
Data on serious adverse events (SAEs) and AEs were collected until the time of the protocol amendment
(29 March 2012). There was no clear evidence of a difference in the incidence of AEs between the two
groups, as shown in Table 21. Six AEs were, however, judged to be ‘probably related’, and five were
judged to be ‘possibly related’ to the use of the device. Two AEs were ‘possibly’ or ‘probably’ attributed
to the use of the device in the control group, in which the device was not used. The reason for this
attribution by the clinical researchers is not clear. Similarly, there was no clear evidence of a difference
between groups in the incidence of SAEs, and only one episode was judged ‘possibly related’ to the use of
the device. Full details of AEs and SAEs are listed in Appendix 7.
Data on ADEs were collected from 29 March 2012 and are summarised in Table 22. A total of 18 ADEs
were recorded in the control group, in which the participants were not exposed to the device. There were
40 ADEs in the intervention group, of which only 25 were judged to be related to the use of the device.
There were no SADEs in either the intervention or the control groups. The full details of ADEs that
occurred during the study are listed in Appendix 8.
TABLE 18 Ulcer-related pain for participants with unhealed ulcers at week 4 and week 24
Baseline 4 weeks
Change from
baseline Adjusted ratio (95% CI) p-value
Number of participants
with unhealed ulcers
509 416
Ulcer-related pain (VAS score), mean (SD)
Usual care 31.5 (29.4) 25.6 (28.5) –4.0 (22.9) – 0.351
Intervention 34.2 (28.8) 23.2 (25.2) –8.7 (26.8) 0.88 (0.68 to 1.14)a
Ulcer-related pain (any pain vs. no pain), n/N (%)
Usual care 195/244 (78%) 137/200 (64%) – 0.853
Intervention 197/245 (77%) 137/195 (65%) 0.95 (0.58 to 1.58)b
Baseline 24 weeks
Change from
baseline Adjusted ratio (95% CI)c p-value
Number of participants
with unhealed ulcers
509 178
Ulcer-related pain (VAS score), mean (SD)
Usual care 31.5 (29.4) 12.7 (21.1) –18.6 (32.0) – 0.282
Intervention 34.2 (28.8) 11.1 (19.8) –23.6 (28.6) 0.81 (0.55 to 1.19)a
Ulcer-related pain (any pain vs. no pain), n (%)
Usual care 195/244 (78%) 59/104 (44%) – 0.83 (0.55 to 1.25)b 0.378
Intervention 197/245 (77%) 51/90 (43%)
SD, standard deviation.
a Ulcer-related pain (continuous VAS score) was log-transformed. The estimate of effect is the ratio of geometric means,
adjusted for baseline ulcer size and grade.
b OR, adjusted for baseline ulcer size and grade.
c Adjusted by baseline ulcer grade, ulcer size and baseline pain.
DOI: 10.3310/hta21340 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 34
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Jeffcoate et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35
TABLE 20 Association between ulcer area change at 4 weeks and final healing
Percentage change in ulcer
area at 4 weeks Unhealed (n= 197) Healed (n= 139)
Adjusted ORa
(95% CI) p-value
Median (IQR) –24% (–48% to 2%) –53% (–75% to –34%) 1.02 (1.01 to 1.03) < 0.001
Minimum, maximum –96%, 87% –98%, 48%
a Adjusted by baseline ulcer grade and ulcer size.
Note
Analysis was restricted to participants with an increase of ulcer area at 4 weeks less than twofold, 33 out of 369 were
excluded. Logistic regression was performed with healing status as outcome and percentage reduction at 4 weeks as
exposure and baseline ulcer grade and size as covariates.
TABLE 19 Ulcer-related pain (VAS score) at 2 weeks and 4 weeks restricted to participants with pain at baseline
Participants with ulcer-related pain Usual care Intervention
Adjusted difference
in meansa (95% CI) p-value
Baseline ulcer-related pain
Mean (SD) 41.4 (28.2) 42.4 (25.3) – –
Median (IQR) 42 (13–65) 43 (21–61)
Minimum, maximum 1, 100 2, 100
n 195 197
Ulcer pain at 2 weeks
Mean (SD) 34.9 (29.5) 33.8 (26) –1.9 (–6.9 to 3.2) 0.472
Median (IQR) 29 (10–56.5) 27 (13–53)
Minimum, maximum 0, 100 0, 92
n 180 183
Ulcer pain at 4 weeks
Mean (SD) 32.6 (28.7) 29.4 (25.9) –3.8 (–8.9 to 1.3) 0.140
Median (IQR) 28 (5–60) 21 (7–50)
Minimum, maximum 0, 100 0, 90
n 173 170
IQR, interquartile range; SD, standard deviation.
a Adjusted by baseline ulcer grade, ulcer size and baseline pain.
Notes
The median per cent reduction in area at 4 weeks was 53% [IQR –75% to –34%] in those who went on to heal by 24 weeks,
compared with 24% (IQR –48% to 25%) in those who remained unhealed (adjusted OR= 1.02, 95% CI 1.01 to 1.03; p < 0.001)
(Table 20). There was no evidence that this association differed according to ulcer area at baseline (interaction OR= 1.00, 95% CI
0.99 to 1.01; p= 0.445) or treatment arm (interaction OR= 0.99, 95% CI 0.97 to 1.00; p= 0.205). Receiver operating
characteristic (ROC) analysis gave an area under the curve (AUC) of 0.78. There was no clear threshold of change in ulcer area at
4 weeks that reliably differentiated between participants who healed and participants who remained unhealed at 24 weeks.
TABLE 21 Incidence of AEs and SAEs prior to the protocol amendment of 29 March 2012
AEs and SAEs Usual care arm Intervention arm
Number of AEs 53 38
Relationship of AEs to the device
None 51 27
Possible 1 5
Probable 1 6
Number of SAEs 21 16
Relationship of SAEs to the device
None 21 15
Possible 0 1
Probable 0 0
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Health economic analysis
Quality-adjusted life-years gained
Health utilities
Although the clinical effectiveness analyses considered the impact of missing data on the primary clinical
outcome, for the purposes of the health economic analysis, we further considered the impact of missing
EQ-5D-3L data on the derivation of utilities. At baseline, 3.5% of the EQ-5D-3L data were missing across
both groups. At 12 weeks, 22% of the data were missing (20% when those who died during this period
were taken into account) and 24% of the data (21% when deaths were accounted for) were missing at
24 weeks, with similar results in both groups. Following the principles set out in the statistical methods for
assessing missing data, multiple imputation was undertaken. Similar to the results of the primary clinical
outcome, imputation slightly reduced the magnitude of effect. Table 23 presents the differences in utilities
derived. The multiple imputed utilities were subsequently used in the cost–utility analysis.
The estimation of QALYs was undertaken as per the same conditions as the clinical outcomes described
earlier to take into account the impact of baseline covariates. When adjusted and unadjusted QALYs were
compared, small differences were found, with unadjusted results showing a 0.0009 (95% CI –0.0210 to
0.00229) QALY gain in favour of intervention versus usual care, and the adjusted results showing a
–0.0019 (–0.0043 to 0.0006) difference in favour of the usual care group. These results are presented in
Table 24. No statistically significant differences were found. In accordance with the analysis plan, the
adjusted QALYs were used in the base case analysis.
TABLE 22 Incidence of ADEs and SADEs after the protocol amendment of 29 March 2012
ADEs and SADEs Usual care arm Intervention arm
Number of SADEs 0 0
Number of ADEs 18 40
Relationship of ADEs to the device
None 14 15
Related 4 25
TABLE 23 EuroQol-5 Dimensions-3 level version utility scores
Assessment
Available cases Cases after multiple imputation
Usual care, EQ-5D-3L
utility score (95% CI)
Heels, EQ-5D-3L
utility score (95% CI)
Usual care, EQ-5D-3L
utility score (95% CI)
(n= 253)
Heels, EQ-5D-3L
utility score
(95% CI) (n= 256)
Baseline 0.438
(0.395 to 0.481)a
0.442
(0.402 to 0.482)b
0.438
(0.396 to 0.479)
0.442
(0.403 to 0.481)
12 weeks 0.480
(0.435 to 0.526)c
0.489
(0.443 to 0.535)d
0.482
(0.445 to 0.520)
0.489
(0.453 to 0.526)
24 weeks 0.511
(0.467 to 0.555)e
0.498
(0.447 to 0.549)f
0.508
(0.473 to 0.543)
0.497
(0.457 to 0.537)
a n= 242 at baseline.
b n= 249 at baseline.
c n= 208 at 12 weeks.
d n= 201 at 12 weeks.
e n= 202 at 24 weeks.
f n= 201 at 24 weeks.
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Costs
The detailed analysis of resource utilisation and costs associated with the intervention compared with usual
care is presented in Appendix 4.
Cost data are inherently skewed, as some participants report £0 resource utilisation while others have
more serious health conditions requiring expensive inpatient admissions. This has the potential to affect
the precision of the mean cost per patient estimates. Therefore, bootstrapping has been used to produce a
sampling distribution of the mean cost from the original sample for the main ITT base case analysis. The
bootstrap results are shown in Table 25 and are in line with the original sample. The overall costs of the
TABLE 25 Intention-to-treat base case costs associated with reported NHS resource use: patients with no reported
NHS resource use includeda
Cost group
Usual care, £ (SD)
(n= 253)
Intervention, £ (SD)
(n= 256)
Mean cost difference,
£ (95% CI) p-value
Unadjusted costs associated with
the heel cast intervention
0 61.18 (69.96) 61.18
(52.588 to 69.768)
–
Adjusted costs associated with
the heel casts intervention
0 31.35 (6.30) 31.35
(30.58 to 32.13)
–
Unadjusted costs associated with
primary and outpatient care
995.36 (1193.36) 896.14 (996.39) –99.22
(–290.58 to 92.14)
0.309
Adjusted costs associated with
primary and outpatient care
932.80 (214.70) 957.96 (205.09) 25.16
(–11.40 to 61.72)
0.177
Unadjusted costs associated with
hospital admissions
1447.25 (3734.79) 1784.89 (4005.41) 337.64
(–336.96 to 1012.23)
0.326
Adjusted costs associated with
hospital admissions
1612.08 (496.55) 1621.98 (495.79) 9.90
(–76.52 to 96.32)
0.822
Unadjusted costs associated with
medication
30.06 (144.90) 16.96 (34.90) –13.11
(–31.41 to 5.20)
0.160
Adjusted costs associated with
medication
22.97 (8.97) 23.97 (8.61) 1.00
(–0.53 to 2.53)
0.200
Unadjusted total costs 2472.67 (4068.71) 2759.16 (4143.48) 286.49
(–428.72 to 1001.70)
0.432
Adjusted total costs 2567.85 (689.61) 2635.26 (687.53) 67.41
(–52.51 to 187.34)
0.270
Bootstrapped adjusted total costs 2567.79 (43.85) 2636.61 (41.24)
SD, standard deviation.
a NHS resource use is defined as reported contacts with primary care, outpatients, hospital admissions and documented
prescribed medication.
Note
The figures in bold are the component costs detailed above all added together to produce the overall mean NHS resource
use cost.
TABLE 24 Unadjusted and adjusted mean QALYs derived from EQ-5D-3L utility scores with multiple imputation
Mean QALY
Usual care (n= 253),
mean QALY (SD)
Intervention (n= 256),
mean QALY (SD)
Mean QALY difference
(between HEELs
intervention and usual
care) (95% CI) p-value
Unadjusted 0.2388 (0.1245) 0.2397 (0.1273) 0.0009
(–0.0210 to 0.0229)
0.934
Adjusted 0.2413 (0.0143) 0.2395 (0.0135) –0.0019
(–0.0043 to 0.0006)
0.133
SD, standard deviation.
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intervention compared with those of usual care alone are also presented in Table 25. The mean per patient
cost of the intervention was £286.49 (95% CI –£428.7 to £1001.70) and was higher than that of the
usual care group, although the difference was not statistically significant. When the adjusted total costs
were compared, this difference was smaller, with a mean cost difference of £67.41 (95% CI –£52.51
to £187.34), and this difference was also not statistically significant. Across the main health-care cost
categories, the intervention was associated with higher costs of hospital admissions, which had a mean
cost difference of £337.64 (95% CI –£336.96 to –£1012.23). This difference was, however, reduced
to £9.90 (95% CI –£76.52 to £96.32) when costs were adjusted. The intervention group had lower
medication costs (cost difference –£13.11, 95% CI £31.41 to £5.20) than the usual care alone group,
and lower primary care/outpatient costs (mean cost difference –£99.22, 95% CI –£290.58 to £92.14), but,
when adjusted costs were examined, costs were slightly higher in the intervention (mean cost difference
£1.00 and £25.16 for medication and primary care/outpatient costs, respectively). No statistically significant
differences were seen in either unadjusted or adjusted costs. As part of the assessment of costs, an
alternative scenario was considered, in which patients with resource utilisation of £0 were excluded from
the analysis; this had no effect on costs. Table 26 shows a similar pattern to the ITT base case results with
no differences between the groups.
Costs per quality-adjusted life-year
Table 27 reports the base case results (based on the adjusted analysis) of the cost–utility analysis. This
indicated that the use of lightweight heel casts in addition to usual care was dominated by usual care
alone (i.e. was more costly and less effective). The ICER was –£35,478.95; bootstrapping generated an
adjusted ICER of –£36,645.04 (95% CI 2.5th –£280,800 to 97.5th £208,378). Similar results were found
TABLE 26 Per-protocol complete case costs associated with reported NHS resource use: patients with no reported
NHS resource use excludeda
Cost group
Usual care,
£ (SD) (n= 222)
Intervention,
£ (SD) (n= 228)
Mean cost difference,
£ (95% CI) p-value
Unadjusted costs associated with the
heel casts intervention
0 65.49 (72.99) 65.49
(55.86 to 75.11)
Adjusted costs associated with the heel
casts intervention
31.47 (6.27) 31.47
(30.64 to 32.30)
Unadjusted costs associated with
primary and outpatient care
1134.35 (1210.57) 1006.19 (1002.01) –128.16
(–333.81 to 77.49)
0.221
Adjusted costs associated with primary
and outpatient care
945.43 (206.45) 962.92 (201.80) 17.49
(–20.33 to 55.31)
0.364
Unadjusted costs associated with
hospital admissions
1649.34 (3945.94) 2004.08 (4192.97) 354.74
(–400.00 to 1109.48)
0.356
Adjusted costs associated with hospital
admissions
1623.51 (498.35) 1632.62 (488.32) 9.12
(–82.29 to 100.53)
0.845
Unadjusted costs associated with
medication
34.26 (154.26) 19.04 (36.45) –15.22
(–35.87 to 5.42)
0.148
Adjusted costs associated with
medication
23.48 (8.66) 24.18 (8.47) 0.70
(–0.89 to 2.28)
0.388
Unadjusted total costs 2817.95 (4230.74) 3094.80 (4272.19) 276.84
(–511.03 to 1064.72)
0.490
Adjusted total costs 2592.41 (686.25) 2651.19 (676.03) 58.78
(–67.43 to 184.98)
0.361
SD, standard deviation.
a NHS resource use is defined as reported contacts with primary care, outpatients, hospital admissions and documented
prescribed medication.
Note
The figures in bold are the component costs detailed above all added together to produce the overall mean NHS resource
use cost.
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(Table 28) when a PP analysis was undertaken, in that the use of lightweight heel casts plus usual care was
dominated by usual care alone, with an ICER of –£10,312.28.
One-way sensitivity analysis
Incremental cost-effectiveness ratios were recalculated based on the lower and upper 95% CIs for
the intervention mean cost differences reported. The only parameter change that estimated that the
lightweight heel cast plus usual care was more cost-effective (£9057.89 per QALY gain) than usual care
alone occurred when the lower-bound estimate of the total mean cost of the intervention was used.
Within the PP analysis, the ICER was £5164.91 per QALY gain for the lightweight heel cast plus usual
care versus usual care alone.
Figure 5 represents the cost-effectiveness plane for all patients of estimates resulting from bootstrapping.
The vertical axis of the plane shows the incremental total costs, and the horizontal axis shows the QALY
gains. This illustrates how the lightweight heel cast plus usual care is dominated by usual care alone,
with the majority of results occurring in the north-west quadrant of the plane.
The CEAC for the base case is shown in Figure 6. The CEAC shows the probability (expressed as a
percentage) of the use of lightweight heel cast plus usual care being a cost-effective intervention against
different willingness-to-pay (WTP) values. Based on a NICE threshold of < £20,000 per QALY gain, the
lightweight heel cast plus usual care would be 5.2%, with a negative net benefit of –£106 (95% CI
–£241 to £19) when a QALY is valued at £20,000.
TABLE 27 Cost per QALY: ITT base case ICER (n= 509) (derived from adjusted costs and QALYs)
Total mean
cost (£)
Incremental
mean cost (£)
Total mean
QALY
Incremental
mean QALY ICER (£)
Usual care 2567.85 0.2413 Dominated
Heels intervention 2635.26 67.41 0.2395 –0.0019 –35,478.95
Sensitivity analysis
Usual care mean estimate 2567.85 0.2413
Heels intervention, lower 95% CI
estimate
2550.64 –17.21 0.2395 –0.0019 9057.89
Mean upper 95% CI estimate 2719.89 152.04 0.2395 –0.0019 –80,021.05
TABLE 28 Cost per QALY – PP complete case costs associated with reported NHS resource use – £0 cost excluded
(derived from adjusted costs and QALYs)
Total mean
cost (£)
Incremental
mean cost (£)
Total mean
QALY
Incremental
mean QALY ICER (£)
Usual care (n= 222) 2592.41 0.2401 Dominated
Heels intervention (n = 228) 2651.19 58.78 0.2391 –0.0057 –10,312.28
Sensitivity analysis
Usual care, mean estimate 2592.41 0.2401
Heels intervention, lower 95% CI
estimate
2562.97 –29.44 0.2391 –0.0057 5164.91
Mean upper 95% CI estimate 2739.41 147.00 0.2391 –0.0057 –25,789.47
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Cost-effectiveness results
The base case results of the analysis are shown in Table 29. The ICER provides an indication of the benefits
of additional healed ulcers relative to the additional costs incurred. The unadjusted ICER is £40.93 per 1%
likelihood increase in healed ulcers at 24 weeks as a result of the intervention. When the adjusted figures
for both costs and outcomes were used, the costs incurred in securing a 1% likelihood increase in healed
ulcers by using the heel cast was £9.63. The cost of generating an additional healed ulcer using a heel cast
would be £963 (95% CI –£745.82 to £2671.82). A one-way sensitivity analysis using the lower-bound
mean cost estimate of the heel cast intervention produced a cost saving of –£246 per additional healed
ulcer, while the upper-bound mean cost estimate was £2172, showing wide variation.
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FIGURE 6 Cost-effectiveness acceptability curve, sensitivity analysis: probability of the HEEL cast being cost-effective.
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FIGURE 5 Cost-effectiveness plane for all patients of estimates resulting from bootstrapping.
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TABLE 29 Cost-effectiveness of healed ulcers
Total adjusted
cost (£)
Incremental
mean cost (£)
Total effect %
probability of
healing
Incremental
difference in %
effect/healing ICER (£)
Usual care 2567.85 37
Heels intervention 2635.26 67.41 44 7 963
Sensitivity analysis
Usual care, mean estimate 2567.85 37
Heels intervention, lower
95% CI estimate
2550.64 –17.21 44 7 –246
Mean upper 95% CI
estimate
2719.89 152.04 44 7 2172
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Chapter 4 Discussion
This trial was designed to investigate whether or not the use of lightweight fibreglass heel casts wouldincrease the number of heel ulcers in patients with diabetes mellitus that healed by 24 weeks. The trial
was undertaken in specialist foot care centres in the UK and was based on comparing the outcomes in
those who were managed with the heel casts in addition to usual care with the outcomes in those
managed with usual care alone. It was powered to detect a difference of 15 percentage points, assuming
an incidence of healing of 40% in the usual care arm. The results of the trial suggest that the true effect
may be smaller than expected, although there was insufficient precision to rule out the possibility that the
intervention had no effect, or even that it had a very small harmful effect. In this respect, it should noted
that there was the possibility of an increase in new ulcers on the contralateral foot of participants in the
intervention group.
Reported adherence to the use of the cast in the intervention group was a median 100%, and compliance
with the protocol was high. Therefore, as expected, a PP analysis did not alter the conclusions of the
primary analysis. The primary analysis was also robust to assumptions about missing data, and there
was no evidence that the intervention was differentially effective in any of a number of prespecified
subgroups. It is possible that a larger sample may provide stronger evidence of a small but still clinically
important effect. It is also possible that the effectiveness of the heel cast is limited to certain populations
or types of ulcer; however, assessing this possibility would almost certainly require a much larger study.
The trial also investigated whether or not the use of a cast was associated with reduction in local pain or
discomfort, as had been suggested by uncontrolled clinical observations. No such effect was demonstrable,
and we found no difference between the intervention and control groups in either the number of patients
reporting any local pain/discomfort or the median pain scores determined using a VAS.
The trial failed to identify any differences between the intervention arm and the control arm in terms of
predefined secondary measures, with the exception of a possible trend towards an increase in the speed of
healing in the intervention group. The isolated finding of a significant difference between groups for one
component of the CWIS questionnaire (see Table 16) may be attributable to chance.
The trial was conducted to a high standard, with recruitment and completion of the required population
being concluded on time. The demographic details of the recruited sample were as expected for a
population with diabetic foot ulcers. The total population for whom a primary outcome was not available
because of withdrawal or any other reason was 84 (16.5%) and lay within the limit set of 25%.
Limitations
A decision was made to base this pragmatic trial on a comparison between standard care alone and
standard care plus the use of heel casts, because the intention was to determine whether or not the
inclusion of heel casts in routine practice in expert centres resulted in clinical improvement. This meant that
the comparator treatment was deliberately chosen as the usual standard of care in the centres selected on
the basis of their specialist interest in the management of foot disease in diabetes mellitus. And even
though the criteria of care were agreed (see Box 3), there was considerable variation documented in the
use of offloading.15 This was, however, assumed to be a reflection of current expert practice in UK. It
should also be noted that there is currently no evidence to suggest that ulcers of the heel should be
managed with non-removable offloading.
An error that was not detected during the course of the study was the failure of some of the clinical
researchers to correctly report the results of the ABPI measurements. However, this had no impact on the
conduct of the study or on the interpretation of the results. Another error was the failure to document the
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prevalence of infection in the two groups at the time of randomisation, even though it was recorded at
every other visit, and the use of antibiotics was recorded when appropriate. There is no reason to suspect
that the distribution of infection differed between the two groups.
There were minor problems relating to the stratification used at the time of randomisation; however, these
were detected early and remedied. Very occasional discrepancies found between the area assessed by
researchers at the time of randomisation and the area later determined by a central blinded observer may
be attributable to the less precise methods of measurement used by the researchers. This resulted in a total
of 24 participants being recruited in error because the ulcer area at baseline was ultimately judged to
be < 25 mm2.
The results of the trial suggest that the incidence of AEs was greater in the intervention group than in the
usual care group. It should, however, be noted that AEs (which were recorded only up until the protocol
change in 29 March 2012) were recorded by researchers who were not blind to randomisation group;
therefore, the data are susceptible to bias. Moreover, none of the observed differences was statistically
significant.
Ancillary analysis
An ancillary analysis was also undertaken to determine whether or not the reduction in cross-sectional area
(with ulcers from both the intervention and control arms combined) by 4 weeks was associated with
eventual healing within 24 weeks, as has previously been reported for other types of ulcer of the foot in
diabetes mellitus.25 There was strong evidence of an association, but ROC analysis failed to identify any
clear threshold value for change in ulcer area at 4 weeks that predicted eventual healing. This issue would
benefit from further research that may inform patient counselling and influence management decisions.
Health economic analysis
There were small differences in costs between the intervention and usual care arms, but none was
statistically significant. When costs were adjusted, the magnitude of differences in cost became smaller.
The results of the incremental cost per QALY analysis did not provide evidence of cost-effectiveness. When
the results of the incremental costs were expressed per percentage increase in likelihood of achieving an
additional healed ulcer, there were differences between the adjusted and unadjusted analyses. With
further examination of the impact on changes in parameter variation around the adjusted base case, there
was wide variation in the results. This uncertainty should be clearly noted in any interpretation of these
results, particularly in the light of the clinical effectiveness results.
Because of the complex nature of diabetes mellitus, it is possible that other factors played a part in the
resources consumed, something that has been identified as an issue in accurately costing the inpatient
management of diabetic foot ulcers.26 Some of the challenges encountered in obtaining accurate data
on resource utilisation must also be acknowledged. Although a patient diary allowed for timely data
collection, this method is, inevitably, rather crude; however, any resultant errors in assigning costs will have
applied to both study groups. It was not possible to explore the costs beyond those to the NHS (e.g. costs
to the patient, loss of productivity) because of limitations of the data collected. One interesting finding is
that the baseline utilities in both groups appeared to be much lower, and the utility gains smaller, than in
other published estimates of diabetes mellitus models and cost–utility evaluations.27 Overall, however, the
results of the health economic analysis did not provide evidence to substantiate the cost-effectiveness of
using lightweight heel casts in the management of heel ulcers in diabetes mellitus.
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Appendix 1 Assessment of ulcer healing in the
definition of the primary outcome
A participant met the criteria for a healed ulcer if their ulcer was judged to have remained healed4 weeks after it was initially judged to be healed by both the on-site research nurse and the blinded
observer. The time to healing was calculated as the number of days between randomisation and the date
of the visit at which the clinical researcher first judged the ulcer to be healed.
A participant’s ulcer was defined as unhealed if:
l it was judged so by the clinical researcher (confirmed by a blinded observer) at 24 weeks and had not
met the criteria for earlier healing defined above, or
l there was a major amputation of the target limb, or
l the participant died during the study prior to the visit at week 24 and had not met the criteria for
healing defined above prior to their death.
The primary outcome was recorded as missing in cases where the participant did not complete the visit at
week 24 (or week 26 or 28 if healing first noted at week 22 or 24, respectively) and was not known to
have died, did not meet the criteria for healing described above and had not had a major amputation of
the target limb.
If the recorded date of verification of ulcer healing by a blinded assessor was outside the required protocol
window (+4 days), the blinded assessor verification was used in the analysis provided that any of the
following criteria were met:
l confirmation by the (blinded) chief investigator that the image was taken on the correct visit date and
shows that the ulcer is healed
l confirmation of healing by a blinded assessor at the site 5, 6 or 7 days after the ulcer was first assessed
as healed by the on-site researcher (protocol violation)
l confirmation of healing by a blinded assessor 4 weeks after initial healing, when the initial healing had
not been confirmed by a blinded assessor
l confirmation by the (blinded) chief investigator that an image taken 2 weeks after initial healing
showed that the ulcer remained healed and that healing was likely to be maintained at 4 weeks
following initial healing.
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Appendix 2 Derivation of binary outcomes for
infection, major amputation, minor amputation
revascularisation of the limb with the target ulcer
or trip or fall leading to hospital admission
l Yes, coded as 1, if at any visit the outcome was reported and related to the target limb.
l No, coded as 0, if at any visit the outcome was not reported or was unrelated to the target limb.
l Coded as missing if the outcome was not reported at any visit and the participant did not attend the
week 24 visit or the information was not completed at the week 24 visit in order to confirm that no
events occurred.
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Appendix 3 Derivation of binary outcomes for
hospital admission, new ulcer on target foot, new
ulcer on contralateral foot
l Yes, coded as 1, if at any visit the outcome was reported.
l No, coded as 0, if the outcome was not reported at any visit.
l Coded as missing if the outcome was not reported at any visits and the participant did not attend the
week 24 visit or the information was not completed at the week 24 visit in order to confirm that no
events occurred.
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Appendix 4 Health economic methods
Introduction
This appendix describes in detail the health economic objectives and methods used for the health
economic evaluation. A summary of the health economic methods used to evaluate the cost-effectiveness
and cost implications of lightweight fibreglass heel casts was provided in the published study protocol.1
This was supplemented by the development of a health economic analysis plan, developed alongside the
SAP. This appendix also provides the rationale for a major amendment to the published health economic
protocol, in which longer-term evaluation of the cost-effectiveness of lightweight fibreglass heel casts and
budget impact analysis were not undertaken. As this substantial amendment to the published protocol
could be questioned, a full rationale for this is presented.
Summary of the decision problem
As discussed in Chapter 1, ulcers of the heel can cause substantial pain and suffering in people affected with
diabetes mellitus. Diabetic foot ulcers are extremely costly and have been estimated to account for 0.7% of
the total UK NHS budget. With the consequences of unhealed and/or recurrent ulcers leading to further
health interventions (including amputation), establishing the cost-effectiveness and clinical effectiveness of
new interventions is warranted. Although other health economic analyses have assessed the cost-effectiveness
of a range of orthotic devices within the context of patient management strategies,28,29 the orthotic devices
assessed have largely been intended for use as preventative strategies across the spectrum of risk categories
for developing an ulcer of the foot, as opposed to being specifically intended for use in the management of
an established ulcer of the heel.
A rapid review of the health economic evidence, completed as part of the preparatory stages of the health
economic analysis, failed to locate specific studies of the cost-effectiveness of lightweight fibreglass heel
casts specific to the patient population described within the trial protocol and setting (either the UK NHS
or another health-care system). Thus, a health economic analysis, alongside a prospective randomised
controlled trial, can provide evidence to support decision-makers in the assessment of whether or not the
use of lightweight fibreglass heel casts is a beneficial intervention in the management and care of people
with a diabetic ulcer of the heel within the UK NHS setting.
Original protocol intentions
In the published protocol,1 it was stated that cost-effectiveness would be assessed by developing a
decision-analytic model to estimate costs and health outcomes, including the percentage of healed ulcers
and QALYs gained. ICERs and cost–utility ratios would be generated for a series of time horizons (including
a lifetime perspective) that reflect the management of people affected by diabetic ulcers of the heel. It was
also stated that a budget impact analysis would be undertaken.
Summary of the major protocol change to the published protocol
Based on the clinical effectiveness results, the plan was to undertake further modelling to assess the
longer-term costs and outcomes of the intervention compared with usual care. The proposed structure was
based on a Markov model with a series of health states to represent healed and unhealed target ulcer,
amputation and death, with the recently published NICE economic evaluation of the cost-effectiveness of
providing custom orthotic footwear to patients at low, moderate and high risk of developing foot ulcers
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identified as a possible model for adaption.26 The adaption proposed would focus on the trial population
as the entry point, that is, those who are already affected, with the trial results being used as the primary
source to estimate required inputs, such as healing time and number of unhealed ulcers. Longer-term
impact would be considered on the basis of the trial results, published literature as part of a rapid review
of the literature (including assessment of the evidence used in the recent NICE model26) and in discussion
with the trial team. A sensitivity analysis was undertaken to account for the uncertainty in key parameters
(one-way sensitivity analysis) and a probabilistic sensitivity analysis was undertaken to quantify the joint
uncertainty in parameter estimates. The aim of undertaking this longer-term modelling was to capture a
more accurate estimation of the cost-effectiveness based on a more realistic explanation of the clinical
pathway and to capture health states (and associated costs/utilities) that may not have been experienced
owing to the short duration of the trial.
Prior to the further development of the model and running of the analysis, the feasibility of undertaking
this longer-term modelling was discussed with the Trial Steering Committee and trial team after initial
consideration of the main clinical results. The evaluation of further long-term modelling was tested against
the feasibility that (a) the intervention would be able to demonstrate clinical effectiveness in the short term,
(b) the trial results would provide a realistic estimation of health states attributed to the intervention (different
healing rates/amputation, etc., and the additional costs and time that these would incur) and (c) the utilities
derived as a result of the intervention could be confidently estimated over a longer period of time.
However, in the light of the clinical effectiveness findings, a decision was made to focus on reporting the
within-trial analysis only. The specific reasons were:
1. On the basis of the trial, there was no evidence that the use of a heel cast could be seen as
clinically effective.
2. The results of the within-trial health economic analysis showed no evidence of cost-effectiveness, based
on the results of the incremental cost per QALY analysis.
3. With a lack of evidence of short-term benefits from using the heel cast, there was no clinical evidence
or opinion that these would or could translate into longer-term benefits.
The justification for undertaking a budget impact analysis was also discussed. Based on the trial findings,
and given the lack of support for the use of lightweight heel casts within the NHS, the Trial Steering
Committee and the trial team decided that the budget impact analysis would be an arbitrary one.
Methods
Patient population
The target population for the health economic analysis was commensurate with the trial population
(see Chapter 2, Participants). Although the SAP set out a subgroup analysis of key variables for the primary
outcome, a subgroup analysis was not proposed in the health economics analysis plan.
Study perspective
The perspective adopted for the health economic analysis was that of the NHS/PSS, in accordance with the
NICE reference case.24 A separate analysis was planned to explore the costs to the patient and their family
(as a result of travel time/time off work) of attending an appointment related to their heel ulcer.
Comparators
As the health economic evaluation was conducted alongside the main trial, the comparators have been
described previously (see Chapter 2, Intervention).
Time horizon
The revised time horizon was based on the trial follow-up duration, that is, 26 weeks (0.5 years).
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Discount rate
As the revised analysis was based on the trial duration only, and thus the duration was < 12 months,
discounting of costs and outcomes was not undertaken.
Collection of resource utilisation and costs
Two main costs were assessed: first, the implementation costs associated with the manufacture and use of
the lightweight heel cast device, and, second, the costs associated with health-care utilisation during the
trial period. In addition, the assessment of costs associated with time away from home or work as a result
of the management of the heel ulcer were included as part of the data collection.
All assumptions made in the calculation of costs were verified by the trial team to ensure that they were
appropriate and commensurate with the trial protocol and/or standard clinical practice. Only resource
usage and associated costs, as part of the management of the target diabetic heel ulcer, were considered.
Implementation costs for the intervention
The costs of training staff in the production and use of the heel cast device were derived from interviews
with the research team and clinical staff. It was estimated that the cost of one heel cast device was £7.00.
Podiatrists in each of the participating study centres were trained in the production of the heel cast, which
involved fashioning of the heel cast device for individual patient requirements, as described in the section
Intervention. All podiatrists were involved in the routine care of patients with diabetic foot ulcers, therefore
the training and time required to mould the heel cast for each patient was included. It was estimated that
it would take a specialist podiatrist 30 minutes to train two podiatrists per study centre in the production
of heel casts. The production of each heel cast device was estimated to take a podiatrist 15 minutes each
time a new product was required.
There is no specific clinical assessment required when considering the suitability of a patient for a heel cast
beyond usual standard care in the assessment of a diabetic heel ulcer. No additional and/or different
dressing or external orthotic footwear is required for the use of the heel cast device. In addition, all
patients, whether or not they received the heel cast device, would receive standard written information,
supplied at each centre, regarding the management and care of their heel ulcer. Although additional
instructions on the use of the heel cast were prepared for the trial, these were estimated to be of minimal
cost (£0.05 per patient for one A4 sheet), and therefore were not included.
Health and Personal Social Services resource utilisation
A bottom-up approach was taken to the collection of patient-level information for additional health and
personal social costs as part of the trial data collection process. Two key data collection tools were used to
collect resource utilisation across key categories:
l A patient log was used to capture resource usage as a result of health-care contacts in primary care
[such as general practitioner (GP) surgery visits] and hospital outpatient care associated with dressing
changes and any further consultations with any health-care professionals as a result of the heel ulcer.
l The trial eCRF was used to collect data on hospital admissions as a result of the diabetic foot ulcer or
heel cast device and medications associated with the treatment of the diabetic ulcer on the target foot.
Patient log
The patient log was developed to capture information that was recorded at each fortnightly assessment
by the researcher, and the participant or carer was asked to keep a simple diary/calendar of relevant
intervening events in order to overcome some of the challenges caused by recall bias and missing data.30
This was deemed particularly important for this patient population, who would probably receive numerous
health-care contacts as a result of the diabetic ulcer and other comorbidities. These data were then
uploaded into the electronic data capture system.
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Information was collected across the following cost categories: primary and outpatient care contacts
(associated with dressing changes/care of the target ulcer); details for all types of visits (e.g. face to face or
telephone call) were collected by recording all resources used, duration of contact and location of contact.
The patient log also contained questions on other resources used, such as travel mileage, public transport
costs or other expenses incurred by the patient. Although the primary analysis would be from a NHS/PSS
perspective, the inclusion of these wider costs would be presented separately to consider the wider costs
to the individual and family.
Missing data considerations in the use of the patient log
Owing to the design of the patient log (reproduced in Appendix 9), which asked patients to report
contacts with health professionals only, rather than tick boxes indicating whether or not a contact had
taken place, it was assumed that the patient had completed the log section only if a contact had occurred
(for interpretation rules of patient responses see Table 31). For logs in which there were blank sections,
it was assumed that where the fields for dressing changes and additional consultations with health-care
professionals were left blank, a dressing change or consultation had not taken place rather than that a
response was missing. A particular problem arose with the capturing of transport detail (including time out
of the house to attend the appointment and the cost associated with this). There were only limited
responses to questions regarding transport costs, and the quality of responses was poor. As this was
intended to be reported separately and not included in the cost calculations for the health economic
analysis, these data were not analysed.
However, a minority of patients did not submit a patient log during their follow-up visit. It is not clear
whether the patients did not return their resource logs because they did not receive any NHS service
provision in the management of their ulcer (i.e. they self-managed their dressing changes) or because
service provision was received but not reported. Further examination was undertaken to assess the
potential impact of the missing patient logs. In total, 465 out of 509 (91%) patients returned a patient log
across the follow-up assessment points, with no pattern of missing data, for example patients who
repeatedly failed to provide a log. When assessed by trial arm, 233 patients assigned to the usual care
group returned a log, while 20 (8%) did not, and 232 intervention patients returned a log, while 24 (9%)
did not. By grade of ulcer, of the 44 not submitting a resource log, 16 (36%) patients had a grade 2 ulcer,
26 (59%) patients had a grade 3 ulcer and two (5%) patients had a grade 4 ulcer.
The pattern of missing data by group and ulcer grade can be summarised as follows.
l In the usual care group, 7 (8%) out of 82 patients with a grade 2 ulcer and 13 (8%) out of 156
patients with a grade 3 ulcer did not return a resource log.
l In the intervention group, 9 (11%) out of 83 patients with a grade 2 ulcer, 13 (8%) out of 158
patients with a grade 3 ulcer and 2 (13%) out of 15 patients with a grade 4 ulcer did not return a
resource log.
It was also noted that 9 of the 44 patients had died (four in the usual care arm and five in the intervention
group), leaving 35 (7%) patients without a single resource log entry. For the 44 patients who did not
report NHS resource use via the patient log, a £0 cost was applied for the base case.
Collection of resources as a result of hospitalisation
Other health resource data were obtained from the trial eCRF. Hospital admission rates were taken from
the eCRF secondary outcomes data and recorded as either yes or no, and included AEs such as minor and
major amputations, revascularisation, falls and serious infection. Details regarding the nature, complexity
and length of stay of each hospital admission for amputations, revascularisation, falls and ‘other’ reasons
(primarily related to systemic infections) were sought from the SAE files. However, the SAE data collection
was largely incomplete for patients and had not been routinely collected. Therefore, standard unit costs
were applied (as shown in Table 30). This was also undertaken in the light of the protocol amendments on
the collection of AE data reported in Chapter 2.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
Collection of medication data
Details of medication prescribed to treat infections of the target foot ulcer were collected via the eCRF
medicine log: drug name, reason for taking the medication, whether or not the patient had started taking
the medication prior to participating in the trial (yes/no), and the dates that the patient had started and
finished taking the medication were noted.
Assumption made in the attribution of costs to resources incurred
Owing to the broad categories within the patient log and the information recorded in the eCRF, challenges
arose in making a precise interpretation of the health-care contacts from the data recorded. Thus, a range
of assumptions were developed and verified by the trial team in order to attribute costs incurred from the
use of resources for each patient. All assumptions were applied consistently across each arm of the trial to
minimise the potential for costs being attributed for reasons unrelated to the intervention (i.e. our focus
was on costs related to management and care according to standard clinical practice for both arms, and,
in the case of the heel cast device arm, to the management of the heel cast itself). These assumptions are
presented in Table 31.
TABLE 30 Unit costs used in the costing of health-care resources utilised: hospital admissions
Secondary care unit costs (from the secondary outcomes data)
Resource use Variable
Unit
cost (£) Source
Hospital attendance since last
visit – and mainly related to
the target foot ulcer
Hosp (y/n)
Hosptarg (y/n)
3848 Hospital admission – Foot ulcer was primary cause
and cost driver
Hospital Episode Statistics 2014, referenced in NICE
Guideline 1926
Patient has had a minor
amputation since last visit on
the foot with the target ulcer
Minor (y/n)
Mintarg (y/n)
6720 Minor amputation is defined as the removal of any
part of the foot below the ankle
Hospital Episode Statistics 2014, NICE Guideline 1926
Patient has had a major
amputation since the last visit
on the foot with the target
ulcer
Major (y/n)
Majtarg (y/n)
10,907 Major amputation is defined as removal of the foot
above the ankle
Hospital Episode Statistics 2014, NICE Guideline 1926
Patient has had
revascularisation surgery on
the foot of the target ulcer
(see Costing methodology)
Rvas (y/n)
Rvastarg (y/n)
7221 Based on HRG codes YQ10A to YQ12D relating to
multiple or single open procedures on blood vessels
of the lower limb
NHS Reference Costs, 2013/1432
Patient admitted to hospital
due to a trip or fall that
affected the target foot
(see Costing methodology)
Fallhosp (y/n)
Falltarg (y/n)
2326 Based on HRG codes WA23 A, B, C – non-elective
long-stay admissions relating to falls without specific
cause. Owing to the nature and complexity of the
trial patient population, only non-elective long-stay
HRG costs were used to calculate a weighted
average cost, as a hospital admission is assumed to
be > 1 day (NEL)
NHS Reference Costs 2013/1432
Hosp, hospital attendance; Hosptarg, hospital attendance mainly related to the target foot; Minor, minor amputation;
Mintarg, minor amputation on the foot with the target ulcer; Major, major amputation; Majtarg, major amputation on the
leg with the target ulcer; Rvas, revascularisation surgery; Rvastarg, revascularisation surgery on the foot of the target ulcer;
Fallhosp, patient admitted to hospital due to a trip/fall; Falltarg, patient admitted to hospital due to a trip/fall that affected
the target foot; HRG, Healthcare Resource Group; NEL, non-elective long-stay inpatient admission.
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TABLE 31 Assumptions made in the costing of patient-level resources, hospital admissions and prescribed
medications
Resource category Assumption made
Patient log: concurrent dressing change
and consultation visits
When a dressing change and consultation with the same health-care
professional were recorded on the same date for a patient, we applied one cost
to the health-care professional’s time
If different NHS staff members were reported for the same record number for
dressing changes and consultation, then both health professionals were
assigned a unit cost and counted
Patient log: hospital doctor A hospital appointment was assumed to be at a consultant-led outpatient clinic
and the appropriate unit cost was applied
Patient log: hospital nurse For hospital-based NHS staff, an appointment with a hospital nurse was
assumed to be a consultation at a nurse-led outpatient clinic and the
appropriate cost was applied
Patient log: outpatient consultations Not all patients specified who they saw when attending a hospital appointment;
alongside the further consultation field are fields for reporting mode of
transport for hospital visits. Some patients reported hospital visits that were
actually admissions to hospital, and these were ignored. For hospital visits
where NHS health-care professional was unspecified but the related transport
field reported transport by car/public transport, it was assumed that this was an
outpatient visit
Patient log: primary care contacts When partial information was collected, for example location of consultation
(home or surgery) and contact type (face to face or telephone consultation),
but not with whom, we assumed this to be a district nurse visit (face to face at
home) or a GP telephone consultation (surgery and telephone call). When a home
visit was recorded as a consultation with no information on the health-care
professional, this was assumed to be with a district nurse
eCRF secondary outcomes: hospital
admissions
When a hospital admission was reported on two consecutive trial visits and the
reason for admission was the same, this was assumed to be one hospital
inpatient episode and a single cost was applied
When a hospital admission was reported for two consecutive trial visits, but the
reason for admission was for two different reasons, these were assumed to be
two different procedures and both procedures were costed
When hospital admissions were reported on non-consecutive trial visits, these
admissions were costed separately
When a patient received an amputation during the trial period, we have not
included costs of follow-up, for example measurement for a prosthetic.
Information captured in the HEELs data set on the types of revascularisation
procedures for patients was insufficient. There are a number of HRG codes
associated with revascularisation procedures based on type, complexity
and mode of procedure. We applied a weighted average cost of open
procedures on blood vessels of the lower limb to calculate a cost associated
with revascularisation
The details of injuries sustained by falls were not clearly captured with the
HEELS data set (within neither the hospital admissions nor the SAE data).
The HEELs trial population was considered to be more susceptible to injury
from a fall; thus, non-elective long-stay HRG codes were used to calculate a
weighted average unit cost
eCRF medicines: long-term medication Only medications related to infection of the target foot ulcer or other related
ulcer event such as cellulitis (following advice from the HEELS clinical team) have
been included
Medication that had been prescribed before the patient’s entry into the trial was
excluded from the analysis
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The resource log questions were divided into two sections. The first related to dressing changes (the
patient was asked to report the NHS staff member) and the second related to other consultations with a
doctor, nurse, podiatrist or other health-care professional). Entries into the resource log were interpreted as
a reported contact taking place. If the field was left blank either for dressing change or other consultation
it was assumed that the patient had no contact with any NHS health professional during that 2-week
period. As such, missing data were viewed as having no contact with NHS professionals.
A range of assumptions were developed and verified by the trial team in order to attribute costs to the
resources incurred for each patient. These are presented in Table 32.
Valuation of costs
All data were valued in monetary terms and unit costs were reported in pounds sterling for the financial
year 2014 (representing the nearest end point of the trial where costs were available). The unit costs were
derived from published unit costs (Personal Social Services Research Unit 2014,31 NHS Reference Costs
2013/14,32 British National Formulary 201433) or from financial information supplied by the trial team.
TABLE 31 Assumptions made in the costing of patient-level resources, hospital admissions and prescribed
medications (continued )
Resource category Assumption made
All medication lists and associated costs (BNF) were checked and verified by the
chief investigator prior to being included in the costing analysis. We assumed
that all medications incurred a cost to the NHS
We excluded medication that was specifically prescribed for infection in the
contralateral foot
We excluded i.v. medications, as it was assumed that these would be costed as
part of the relevant HRG for that hospital admission
We excluded medication that was not related to an infection of the target ulcer,
for example medication taken to treat a urinary tract infection or a chest
infection
All medications were related to those prescribed and taken while patients
were treated in the community, that is, for hospital discharge, outpatient
consultations and/or primary care. We have assumed that the lowest price
generic brand medication as stated in the BNF unless a brand name is
specifically stated in the medication data set
When misspellings or abbreviations have been used we have costed to the
lowest price generic band. When dosage was missing, the HEELS trial team
advised on the correct dosage for costing purposes
For some patients, it was noted that medication therapy was ongoing and an
end date was not available or not collected before the end of the trial. In these
instances, a median number of days prescribed was calculated for each drug
and used as a substitute for prescriptions with missing end dates
BNF, British National Formulary; HRG, Healthcare Resource Group; i.v., intravenous.
Notes
Of 250 reported outpatient consultations, 207 (83%) were reported as hospital doctor consultations and 43 (11%) were
reported as ‘hospital’ visits – clinic lead unknown.
Usual care: 160 reported outpatient visits; 76% consultant led, 24% clinic lead unknown.
Heels: 90 reported outpatient visits; 96% consultant led, 4% clinic lead unknown.
The usual care group had more outpatient visits for which the clinic lead was unspecified, which may have underestimated
usual care costs in this area. However, the usual care group still had higher costs related to outpatient consultations
compared with the intervention.
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Calculating the unit cost of revascularisation therapy
As the type, complexity and mode of hospital delivery of revascularisation treatment was unknown, the weighted
average cost of open procedures on blood vessels of the lower leg was calculated as shown in Table 33.
Calculating the unit cost of falls relating to the foot with the target ulcer
that resulted in a hospital admission
As the details of injuries sustained due to falls were not clearly captured and the trial population was
considered to be more susceptible to injury due to a fall, non-elective long-stay Healthcare Resource Group
codes were used to calculate a weighted average unit cost as shown in Table 34.
TABLE 32 Unit costs used in the costing of health-care resources utilised: primary and community care
Primary and community care costs (from the patient log data)
Resource use Variable
Unit
cost (£) Source
NHS staff carrying out
dressing changes (Dress
who); number of dressing
changes (recno)
District nurse 39 Mean average cost for a one-to-one contact –
PSSRU 201431
Practice nurse 10.25 Average patient contact: 15.5 minutes – PSSRU
201431
Podiatrist (specialist) 49 Mean average cost for a one-to-one contact
Grade 6 – PSSRU 201431
Hospital nurse – has been
classified as referring to
nurse-led outpatient
consultations
69 As the specific reason for an outpatient
consultation is unknown, only that it is related to
the target ulcer, the weighted average cost by
attendance activity has been used – NHS Reference
Costs, 2013/1432
Research nurse/podiatrist 49 Included as the results suggest that the research
nurse/podiatrist was utilised in place of usual care
NHS staff
Costed as Grade 6 specialist podiatrist – PSSRU 201431
Consultations with
health-care professionals:
related to target foot;
type of consultation;
where face to face took
place; (visit who); (foolrel);
(contype); (ffloc)
GP consultation – in person 46 Average surgery contact: 11.7 minutes – PSSRU
201431
GP consultation – by
telephone
28 Average telephone consultation: 7.1 minutes –
PSSRU 201431
GP consultation – home
visit
115 Per out-of-surgery visit lasting 23.4 minutes –
PSSRU 201431
Practice nurse appointment 10.25 Average patient contact: 15.5 minutes – PSSRU
201431
Clinic provided in GP
practice
67 Average clinic contact: 17.2 minutes – PSSRU
201431
District nurse 39 Mean average cost for a one-to-one contact –
PSSRU 201431
Podiatrist grade 6
(specialist)
49 Mean average cost for a one-to-one contact
Grade 6 – PSSRU 201431
Outpatient 111 Weighted average by attendance activity – NHS
Reference Costs, 2013/1432
Hospital consultant-led
outpatient appointment
128 Weighted average by attendance activity – NHS
Reference Costs, 2013/1432
PSSRU, Personal Social Services Research Unit.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
TABLE 33 Unit costs of revascularisation
Currency code Currency description (all HRGs combined)
Total HRG
activity
National average
unit cost (£)
YQ10A Multiple open procedures on blood vessels of lower
limbs with CC score 11+
283 14,366
YQ10B Multiple open procedures on blood vessels of lower
limbs with CC score 7–10
560 10,719
YQ10C Multiple open procedures on blood vessels of lower
limbs with CC score 4–6
929 8194
YQ10D Multiple open procedures on blood vessels of lower
limbs with CC score 0–3
1028 6610
YQ11A Single open procedure on blood vessel of lower
limb with imaging intervention, with CC score 7+
292 12,170
YQ11B Single open procedure on blood vessel of lower
limb with imaging intervention, with CC score 4–6
417 8660
YQ11C Single open procedure on blood vessel of lower
limb with imaging intervention, with CC score 0–3
421 6849
YQ12A Single open procedure on blood vessel of lower
limb with CC score 11+
329 11,323
YQ12B Single open procedure on blood vessel of lower
limb with CC score 7–10
786 7474
YQ12C Single open procedure on blood vessel of lower
limb with CC score 4–6
1668 6211
YQ12D Single open procedure on blood vessel of lower
limb with CC score 0–3
2636 4939
CC, Complications and Comorbidities; HRG, Healthcare Resource Group.
Note
Little information was collected describing the type, complexity or mode of delivery (i.e. elective, non-elective long/short
stay) of a revascularisation procedure. Therefore, the ‘Total HRG activity’, combining all procedures, was used to calculate
the weighted average.
TABLE 34 Unit costs of falls
WA Falls
Number
of FCE
National average
unit cost (£)
Non-elective long stay HRG codes and unit costs (length of stay > 1 day)
WA23A Falls without specific cause, with CC score 4+
(mean LOS 13.34 days)
259 4128
WA23B Falls without specific cause, with CC score 2–3
(mean LOS 7.74 days)
898 2672
WA23C Falls without specific cause, with CC score 0–1
(mean LOS 3.57 days)
931 1491
CC, Complications and Comorbidities; FCE, full consultant episode; HRG, Healthcare Resource Group; LOS, length of stay.
Note
Falls were assumed to be accidental injuries and hospital admission would be non-elective in nature. A weighted average
cost of non-elective long-stay admissions was calculated.
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Costing methodology
Hospital admission rates were taken from the secondary outcomes data, and more details regarding the
nature, complexity and length of stay of each hospital admission for amputations, revascularisation, falls
and ‘other’ reasons (primarily related to systemic infections) was sought from the SAE files. However, the
SAE data collection was largely incomplete for patients who had reported a hospital admission and had not
been routinely collected. Little information was collected describing the type, the complexity or the mode
of delivery (i.e. elective, non-elective long/short stay) of a revascularisation procedure. Therefore, the ‘total
Healthcare Resource Group activity’, combining all procedures, was used to calculate the weighted average.
It was assumed that falls were accidental injuries and that hospital admission was non-elective in nature.
A weighted average cost of non-elective long stay admissions was calculated using full consultant episodes.
For this reason, already compiled unit costs from the literature and national reference costs were used to
cost hospital admissions (see Table 32). For every trial participant, treatment costs were calculated by
multiplying each individual resource use by an appropriate unit cost. These costs were added to produce
a total cost for each participant during the trial. These totals were then summated for each trial arm.
Outcomes used in the economic analysis
Two outcomes were used in the evaluation of cost-effectiveness, (1) the percentage of healed ulcers at or
before 24 weeks and (2) the EQ-5D-3L, in order to generate QALYs.
Clinical outcome
The primary clinical outcome (healing first identified at or before 24 weeks from randomisation) was used
to describe the percentage of healed ulcers obtained in the intervention plus usual care) versus usual care
alone. No further analysis was done, that is, to ensure consistency in reporting with the clinical end point,
the percentage of healed ulcers was taken directly from the primary analysis undertaken.
Patient-reported (preference-based) outcome
The EQ-5D-3L is a generic, single-index, preference-based health-related quality of life instrument. It
measures health-related quality of life on five dimensions with three levels for each (35 = 243). A tariff of
utility values associated with each of the 243 possible combinations (health states), based on a social
survey in the UK using the time trade-off method, is provided by the EuroQol Group.
As the EQ-5D-3L was included within the trial as one of the secondary patient-related outcomes, the main
SAP reported the methods used to analyse the EQ-5D-3L in order to record patient-reported changes in
health outcomes, using the EQ-5D-3L VAS and EQ-5D-3L descriptive system to report changes in health
status and utilities, respectively. Thus, the economic analysis focused on utilising the utilities derived from
the EQ-5D-3L in order to generate QALYs.
The utilities derived from the EQ-5D-3L were thoroughly investigated with the trial statisticians to ensure
that, when required, (a) results obtained were commensurate, and (b) additional or extended interrogation
of the EQ-5D-3L requiring deviation from the main statistical analysis or findings was fully discussed. These
changes were predominantly as a result of the EQ-5D-3L being a secondary end point within the main trial
and thus were not subjected to elements expected within a health economic analysis (e.g. assessment of
the impact of missing data).
The following additional analyses were undertaken for the health economic analysis.
At baseline, the EQ-5D-3L sample contains < 5% of cases with missing values (3.5%), which can be
considered to be missing at random. At the 12-week time point, 22% of the data were missing, and at
the 24-week time point 24% of the data were missing. Patients who died during the study were given a
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value of 0 at the appropriate time point. This meant that 3.5% of the data were missing at baseline,
20% were missing at 12 weeks and 21% were missing at 24 weeks. To evaluate whether or not the
missing EQ-5D-3L data across the time points was missing at random, Little’s chi-squared test was
undertaken, with the null hypothesis that the data were missing completely at random and the p-value set
at the 0.05 significance level. The variables used to examine whether or not associations between patient
characteristics and missing EQ-5D-3L data existed were age, sex, immobility status, diabetes mellitus type
and exudate category. The results of Little’s missing completely at random test show that missing data can
be considered missing completely at random. Multiple imputation of missing EQ-5D-3L data was then
undertaken. The following predictor variables were used: age, sex, immobility status, diabetes mellitus type
and exudate type. The number of imputations performed was 20.
Generation of quality-adjusted life-years
Quality-adjusted life-years were calculated using AUC, with the area under a health state calculated from
the duration of that health state multiplied by the weight for that health state to estimate the QALYs
gained. As the total trial follow-up duration was 0.5 years, this produced a QALY gain for this time period.
The QALY per patient was derived from the multiply imputed EQ-5D-3L data set. The QALY derived was
adjusted for baseline covariates as per the statistical analysis (adjustment for grade of ulcer and size of
ulcer area). Mean QALY differences were calculated using independent samples t-test with 95% CIs.
Health economic analysis
Cost–utility analysis
Analysis (incremental cost-effectiveness ratios)
Base case
As the trial was set up to be analysed under ITT principles, for consistency the base case for the health
economic analysis was conducted following these principles: ICERs were computed by presenting
incremental costs and effects and subsequent ICER in order to allow easily reproducible calculations to be
made, with 95% CIs derived from bootstrapping. Given the impact that missing data could have on the
health economics results, further analysis was undertaken to assess the impact of the ICER when missing
cost data were taken into account. As part of the assessment of costs, an alternative scenario was
considered, in which patients with resource utilisation of £0 were excluded from the analysis (PP sample).
An ICER calculating the cost of generating an additional healed ulcer was also calculated.
The ICER is represented as:
Heels intervention cost−usual care cost
Heels intervention effect−usual care effect
. (1)
The scenario could arise in a cost-effectiveness analysis in which one strategy is both more effective and
less costly. In this situation, this strategy would be considered to dominate the other strategy. In such a
situation, the ICER becomes negative and the numerical value would be uninformative. In these situations,
the dominating strategy can then be seen as preferred regardless of any consideration of budget.
Sensitivity analyses
In order to assess uncertainty in the estimation of the ICERs, deterministic one-way sensitivity analyses of
the total NHS resource use cost were undertaken using the lower- and upper-bound value of the 95% CI
for the Heels intervention total NHS resource use cost and the usual care mean total NHS resource use
cost, as shown in Table 35.
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Bootstrapping and cost-effectiveness acceptability curve
Non-parametric bootstrapping using 1000 replications was undertaken to estimate the probability of the
intervention being cost-effective across a range of cost-effectiveness threshold values, plotted as CEAC.
For the cost–utility analysis, the probability of the intervention representing value for money using NICE
threshold values of £20,000–30,000) would be presented.
In general, NICE considers an intervention cost-effective if one of the following applies.
l Where an intervention is less costly and more clinically effective than all other relevant alternatives.
In this case, the reporting of an ICER becomes meaningless, as the strategy in question dominates
the alternative
l Below a most plausible ICER of £20,000 per QALY gained, the decision to recommend the use of a
technology is normally based on the cost-effectiveness estimate and the acceptability of a technology
as an effective use of NHS resources
l As the ICER of an intervention increases in the range of £2000 to £30,000 per QALY, judgement about
the acceptability of the technology as an effective use of NHS resource will make explicit reference to
other relevant factors, as set out in the guidelines.24
Net monetary benefit
In addition, net-benefit analysis was used to determine whether or not the heel cast intervention can be
considered cost-effective in terms of the decision-maker’s WTP threshold of £20,000. The net benefit
statistic is based on the value of the WTP threshold, and if the net benefit produced is positive (> £0), then
the intervention can be considered cost-effective. However, a negative net benefit (< £0) indicates that the
intervention is not cost-effective, as any benefits of the intervention are outweighed by its costs.
Cost-effectiveness analysis
For the cost-effectiveness analysis, the primary clinical end point to derive the outcome was used, with
costs estimated as described above. A series of one-way sensitivity analyses were undertaken based on the
distribution (95% CIs) of the total NHS resource use cost parameters identified from the main analysis.
All analyses were conducted in IBM SPSS Statistics version 22 (IBM Corporation, Armonk, NY, USA).
TABLE 35 Sensitivity analysis cost parameter change for ICER calculation
Parameter varied Result
ITT base case mean cost AND cost-effectiveness of healed ulcers –
adjusted lower 95% CI limit
Heels lower estimate of £2550.64 vs. usual care
mean estimate of £2567.85 cost per patient
ITT base case mean cost AND cost-effectiveness of healed ulcers –
adjusted upper 95% CI limit
Heels upper estimate of £2719.89 vs. usual care
mean estimate of £2567.85 cost per patient
PP complete case costs associated with reported NHS resource use
(£0 cost excluded) – adjusted lower 95% CI limit
Heels lower estimate of £2562.97 vs. usual care
mean estimate of £2592.41 cost per patient
PP complete case costs associated with reported NHS resource use
(£0 cost excluded) – adjusted upper 95% CI limit
Heels upper estimate of £2739.41 vs. usual care
mean estimate of £2592.41 cost per patient
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Appendix 5 Reasons documented by researchers
for not recording ankle brachial pressure index in
152 participants
Sixty-five cases
In 65 cases, ABPI was not recorded but was likely to have been > 1.4 because the reading was said to be
too high or the vessel non-compressible, calcified or equivalent.
Twenty-nine cases
In 29 cases, ABPI could not be measured because of pain, ulceration, fragile skin, wound dressing or oedema.
Fifty-eight cases
In 58 cases, no clear clinical reason was provided.
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Appendix 6 Details of documented protocol
violations
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Appendix 7 Details of adverse events and serious
adverse events in 113 participants recruited prior to
the protocol change on 29 March 2012
SAEs Usual care (n= 57) Intervention (n= 56)
Any SAE during study 14 12
Number of SAEs 21 16
SAE preferred term
Angioplasty 2 0
Cerebrovascular accident 1 0
Chest pain 1 0
Chronic obstructive pulmonary disease 2 0
Death 1 2
Debridement 0 1
Diabetic ketoacidosis 0 1
Femoral neck fracture 0 1
Gangrene 0 1
Gastrointestinal infection 1 0
Grand mal convulsion 0 1
Hypoglycaemia 1 0
Infected skin ulcer 0 1
Infection 1 1
Localised infection 1 0
Myocardial infarction 1 2
Opiates 1 0
Osteomyelitis 0 1
Paralysis 0 1
Pneumonia 2 0
Renal failure 1 0
Sepsis 0 1
Skull fracture 1 0
Soft tissue infection 1 0
Tibia fracture 1 0
Transient ischaemic attack 0 2
Urinary tract infection 1 0
Vascular test 1 0
SAE relationship to device
None 21 15
Possible 0 1
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AEs Usual care (n= 57) Intervention (n= 56)
Any AE during study 24 22
Number of AEs 53 38
AE preferred term
Abdominal pain 1 0
Abscess drainage 1 0
Angioplasty 2 0
Application site erosion 0 1
Application site rash 1 0
Application reaction 0 1
Blister 0 1
Cellulitis 2 0
Cerebrovascular accident 1 0
Chest pain 2 0
Chronic obstructive pulmonary disease 2 0
Contusion 1 0
Coronary artery bypass 0 1
Death 2 2
Debridement 1 5
Decreased appetite 1 0
Diabetic ketoacidosis 0 1
Erythema 0 2
Fall 1 0
Femoral neck fracture 0 1
Foot operation 1 0
Gangrene 0 1
Gastrointestinal infection 1 0
Grand mal convulsion 0 1
Hypoglycaemia 1 0
Infected skin ulcer 3 3
Infection 3 1
Localised infection 8 0
Loss of consciousness 0 1
Mobility decreased 1 0
Muscular weakness 1 0
Myocardial infarction 1 2
Opiates 1 0
Osteomyelitis 0 4
Paralysis 0 1
Paronychia 0 1
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AEs Usual care (n= 57) Intervention (n= 56)
Pneumonia 2 0
Postoperative wound 1 1
Renal failure 1 0
Respiratory tract infection 1 0
Sepsis 0 1
Skin injury 0 2
Skin ulcer 1 2
Skull fracture 1 0
Soft tissue infection 2 0
Tibia fracture 1 0
Transient ischaemic attack 0 2
Urinary tract infection 1 0
Vascular test 1 0
Wound complication 1 0
Wound necrosis 1 0
AE relationship to offloading device
None 51 27
Possible 1 5
Probable 1 6
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Appendix 8 Summary of adverse device effects
(collected from 29 March 2012)
ADEs Usual care (n= 253) Intervention (n= 256)
Any SADEs during study 0 0
Any ADE during study 15 31
Number of ADEs 18 40
ADE preferred term
Amputation 0 1
Application site erosion 1 6
Application site reaction 0 1
Application site ulcer 0 2
Debridement 0 1
Deep-vein thrombosis 1 0
Diarrhoea 0 1
Excoriation 0 1
Foot fracture 0 1
General symptom 1 0
Haematoma 1 0
Hospitalisation 1 0
Hypoglycaemia 0 1
Infected skin ulcer 3 1
Infection 2 2
Leg amputation 1 0
Limb injury 0 1
Lower respiratory tract infection 0 1
Necrosis 1 0
Onychomadesis 1 0
Postoperative wound infection 0 1
Skin ulcer 4 9
Skin wound 0 1
Ulcer 0 1
Urinary tract infection 0 1
Wound 0 2
Wound decomposition 0 3
Wound secretion 0 1
Wound sepsis 1 0
ADE relationship to offloading device
Not related 14 15
Related 4 25
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Appendix 9 Copy of patient resource log
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Appendix 10 Analysis of resources used and costs
This appendix describes in detail the analysis of the resources used and associated costs as a result of theintervention compared with usual care.
Implementation of the intervention and costs
The implementation of the intervention incurred initial costs of training podiatrists in each participating
centre and of producing the lightweight heel cast device for each patient, in addition to the cost of the
device itself. The training costs were estimated from discussion with the trial team, based on the estimation
that 30 minutes of training delivered by a specialist podiatrist would be required at each of the 35 centres,
with two podiatrists in each centre receiving the training. that 30 minutes of training delivered by a
specialist podiatrist would be required at each of the 35 centres, with two podiatrists in each centre
receiving the training. The initial cost of producing the first heel cast for each participant was calculated for
all participants in the intervention group.
During the trial, participants in the intervention group may also have received a subsequent Heels device
owing to damage or other reasons. The additional costs of subsequent Heels devices were captured from the
patient diaries, and thus relied on participants self-reporting that they had received a new one. In the 115
participants who reported receiving at least one replacement device, a wide range in number of replacement
devices was reported (median, 3; range 1–24), see Table 36. The total number of replacement devices
(n = 513), with podiatrist time included, was used to estimate the costs of replacement.
TABLE 36 Number of replacement lightweight heel casts used in intervention group
Mean (SD) 4.46 (4.97)
Median (25th centile, 75th centile) 3.00 (1.00, 5.00)
Minimum, maximum 1, 24
SD, standard deviation.
The implementation costs for the intervention are summarised in Table 37. The mean implementation cost
for the intervention was estimated to be £61.18.
Life span of the first heel cast applied at baseline/week 0
The number of days between the first heel cast being applied to a patient’s heel ulcer at baseline (week 0)
and the first date a patient reported that a new heel cast had been made (alongside the date of a dressing
change) was examined, and the results are displayed in Table 38, which shows the number of days before
a new heel cast was reported by any patient with no differentiation between grade of ulcer. In Table 39,
the number of days reported when a new heel cast was applied is examined by the grade of ulcer. The
median number of days before a new heel cast was reported was 14 for all grades of ulcers. The mean
number of days was 30 (mean days for grade 2 ulcers = 27, grade 3= 32.5, grade 4 = 26). After this initial
reporting of receiving a new heel cast, it is difficult to tell if subsequent reports of new heel casts are a
reflection of a patient continuing to receive necessary new heel casts, or if a patient is continuing to report
they have a new heel cast – the same one. In the majority of cases, there is continued reporting of new
heel casts every 2 weeks, which has likely led to an overestimation of the number of replacement heel
casts required.
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TABLE 37 Summary of implementation costs of the intervention
Resource use Unit cost (£) Source of unit cost
Cost per
component
(£)
Staff costs
Specialist podiatrist providing training for 30 minutes for
35 trusts
21 PSSRU 201431 735
One-off training cost of two specialist podiatrists per trust
(35 trusts in the trial)
42 PSSRU 201431 1470
Heel cast costs: first cast
Cost of initial heel cast per patient in the trial (256 patients) 7 Trial team 1792
Staff time to produce the initial heel cast per patient
(15 minutes)
10.50 PSSRU 201431 2688
Heel cast costs: additional casts
Additional heel casts (n= 513) 7 Trial team 3591
Time taken by specialist podiatrist to produce a new heel cast
(15 minutes per each of the 513 new heel casts)
10.50 PSSRU 201431 5386.50
Total cost 15,662.50
Mean cost per patient (256 patients) 61.18
TABLE 38 Number of days between first heel cast being applied at baseline and the patient and a new heel cast
being applied: all ulcers
Mean days (SD) 30.46 (35.01)
Median days (25th centile, 75th centile) 14 (11.25, 35.00)
Minimum, maximum days 1, 194
SD, standard deviation.
TABLE 39 Number of days between first heel cast being applied at baseline and the patient and a new heel cast
being applied: by grade or ulcer
Grade 2 (n= 35)a Mean days (SD) 26.91 (25.22)
Median days (25th centile, 75th centile) 14 (9.00, 35.00)
Minimum, maximum days 1, 115
Grade 3 (n= 73) Mean days (SD) 32.49 (39.03)
Median days (25th centile, 75th centile) 14 (10.50, 37.50)
Minimum, maximum days 1, 194
Grade 4 (n= 6) Mean days (SD) 26.33 (35.56)
Median days [25th centile, 75th centile] 14 [10.75, 37.25]
Minimum, maximum days 1, 98
SD, standard deviation.
a One patient in this group did not report dates of dressing/heel cast change.
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Summary of resource utilisation and costs associated with HEELs in
primary and outpatient care
Dressing changes
The usual care group reported more instances of dressing changes than the intervention group (Table 40),
and made significantly more reports of self-managed ulcer care than the intervention group. The
intervention group reported lower rates of dressing changes, but of those dressing changes there were
slightly higher rates attributed to NHS practitioners than in the control group. None of these differences
was statistically significant.
The mean cost of dressing changes was £821.28 in the usual care group and £724.76 in the intervention
group. Overall costs associated with dressing changes were £96.52 lower in the intervention group than in
the usual care group, but the difference was not statistically significant (Tables 41 and 42).
Health-care consultations (primary care and hospital outpatient visits)
Aside from reporting the mode of dressing change for the target heel ulcer, patients were asked if they
had consulted any other health-care practitioners regarding the care of their heel ulcer. Table 43
summarises the health-care consultations reported by participants for a consultation regarding their target
heel ulcer. These consultations may have occurred in the same week as a dressing change performed by
another health-care practitioner (such as a district nurse or a podiatrist), or may have occurred without a
dressing change being reported. Many patients reported a dressing change and a consultation with the
same health-care professional during one week. It was assumed in such cases that the dressing change
and the consultation (for example with a district nurse or a podiatrist) occurred at the same time. In such
cases, a unit cost was applied only once to avoid double costing the same appointment. For outpatient
appointments, if a patient reported seeing a ‘hospital doctor,’ this was assumed to be at a consultant-led
outpatient clinic, and so the consultant-led outpatient clinic unit cost was applied. If a patient reported
attending a hospital clinic without describing the health-care professional seen, then the generic cost for
an outpatient appointment was applied. In total, 105 patients reported an outpatient visit, with 93 (89%)
reporting seeing a ‘hospital doctor’ and 12 (11%) not specifying who they saw. Of the participants who
reported attending a health-care consultation, participants receiving usual care reported more hospital
outpatient consultations than those receiving the intervention, but this difference was not statistically
significant. There were similar numbers of primary care contacts across the different categories, with no
statistically significant differences.
The costs of primary care and outpatient consultations are reported in Table 44. The number of outpatient
visits in which the clinic lead was unspecified was higher in the usual care group, which may have led us to
underestimate usual care costs in this area. However, even so, costs related to outpatient consultations
were higher in the usual care group than in the intervention group. Overall, mean cost per participant was
slightly higher in the usual care group than in the intervention group (£1182.00 vs. £1072.00), but the
difference was not a statistically significant; the mean cost difference was £110.26 (95% CI –£101.10 to
£321.63; p = 0.306).
Hospital admissions and associated costs
Following our costing methodology (see Appendix 4), the total number of hospital admissions costed was
43 (17%) in the usual care group, compared with 56 (22%) in the HEELs group. An overall summary of
the number and cost of hospital admissions is reported in Table 45. Reasons for admissions were
amputation (minor/major), revascularisation, falls and other less defined reasons reported as specifically
related to the target heel ulcer and were, in the majority of cases, accompanied by systemic infection.
Many patients reporting hospital admissions spent more than one spell in hospital during the trial.
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TABLE 40 Number of dressing changes reported
Dressing changes Usual care (n= 253) Intervention (n= 256)
Total number of
visits (n= 509)
Mean difference
(95% CI); p-value
District nurse
Mean (SD) 9.45 (19.52) 9.1 (17.82) 2391 usual 0.35 (–2.90 to 3.60);
p = 0.463
Median (25th centile,
75th centile)
0 (0, 9) 0 (0, 10) 2330 HEELs
Minimum, maximum 0, 137 0, 129
Practice nurse
Mean (SD) 4.43 (10.74) 4.24 (12.60) 1120 usual 0.19 (–1.85 to 2.22);
p = 0.941
Median (25th centile,
75th centile)
0 (0, 2) 0 (0, 1) 1086 HEELs
Minimum, maximum 0, 76 0, 115
Community/hospital podiatrist
Mean (SD) 3.45 (7.07) 3.11 (6.02) 873 usual 0.34 (–0.80 to 1.48);
p = 0.558
Median (25th centile,
75th centile)
0 (0, 4) 0 (0, 2) 796 HEELs
Minimum, maximum 0, 57 0, 42
Outpatient visit – nurse led
Mean (SD) 1.43 (5.25) 0.98 (3.29) 363 usual 0.45 (–0.31 to 1.21);
p = 0.246
Median (25th centile,
75th centile)
0 (0, 0) 0 (0, 0) 252 HEELs
Minimum, maximum 0, 47 0, 32
Research nurse/podiatrist
Mean (SD) 2.84 (4.69) 2.16 (4.06) 719 usual 0.68 (–0.09 to 1.44);
p = 0.082
Median (25th centile,
75th centile)
0 (0, 4) 0 (0, 2) 554 HEELs
Minimum, maximum 0, 27 0, 28
Family member
Mean (SD) 5.32 (17.75) 5.16 (19.86) 1346 usual 0.16 (–3.12 to 3.44);
p = 0.922
Median (25th centile,
75th centile)
– – 1320 HEELs
Minimum, maximum 0, 165 0, 179
Self
Mean (SD) 6.41 (24.13) 2.62 (10.10) 1622 usual 3.79 (0.58 to 7.01);
p = 0.021
Median (25th centile,
75th centile)
– – 670 HEELs
Minimum, maximum 0, 193 0, 74
Friend or carer
Mean (SD) 0.84 (8.02) 0.98 (9.10) 213 usual –0.14 (–1.64 to
1.35); p = 0.852
Median (25th centile,
75th centile)
– – 252 HEELs
Minimum, maximum 0, 123 0, 118
SD, standard deviation.
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Costs of medications (antibiotics)
Of the 509 patients, 209 patients (107 in the usual care group and 102 in the intervention grou) reported
receiving prescribed medication for an infection related to the target heel ulcer. For those prescribed
medication, the mean cost of antibiotics was £71.09 in the usual care group and £42.56 in the
intervention group, but the difference was not statistically significant (£28.53, 95% CI –£14.63 to £71.68;
p = 0.194. Table A9.10 below provides a descriptive analysis of the medications prescribed for infections
related to the target foot ulcer (Table 46).
TABLE 41 Total costs (£) associated with dressing changes
Usual care (n= 253) Intervention (n= 256) Mean cost difference (95% CI) p-value
Mean (SD) 821.28 (1037.67) 724.76 (831.63) 96.52 (–67.15 to 260.18) 0.247
TABLE 42 Mean costs (£) of dressing changes, per mode of dressing change
Mode of dressing change
Usual care
(n= 253)
Intervention
(n= 256)
Total cost
(n= 509)
Mean difference (95% CI);
p-value
District nurse
Mean (SD) 368.57 (761.27) 354.96 (694.88) 93,249.00 usual 13.61 (–113.29 to 140.52);
p= 0.833
Median (25th centile,
75th centile)
0 (0, 351.0) 0 (0, 390.0) 90,870.00
HEELs
Minimum, maximum 0, 5343 0, 5031
Practice nurse
Mean (SD) 45.38 (110.04) 43.48 (129.13) 11,480.00 usual 1.89 (–19.01 to 22.80);
p= 0.859
Median (25th centile,
75th centile)
0 (0, 20.5) 0 (0, 10.25) 11,132.00
HEELs
Minimum, maximum 0, 779 0, 1178.75
Community/hospital podiatrist
Mean (SD) 169.08 (346.35) 152.36 (294.97) 42,777.00 usual 16.72 (–39.28 to 72.72);
p= 0.558
Median (25th centile,
75th centile)
0 (0, 147) 24.50 (0, 196) 39,004.00
HEELs
Minimum, maximum 0, 2793 0, 2058
Outpatient visit – nurse led
Mean (SD) 99.0 (362.10) 67.92 (227.17) 25,047.00 usual 31.08 (–21.50 to 83.65);
p= 0.246
Median (25th centile,
75th centile)
0 (0, 0) 0 (0, 51.75) 17,388.00
HEELs
Minimum, maximum 0, 3243 0, 2208
Research nurse/podiatrist
Mean (SD) 139.25 (229.82) 106.03 (199.08) 35,231.00 usual 33.21 (–4.22 to 70.64);
p= 0.082
Median (25th centile,
75th centile)
0 (0, 196) 0 (0, 98) 27,146.00
HEELs
Minimum, maximum 0, 1323 0, 1372
SD, standard deviation.
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TABLE 43 Number of health-care consultations reported
The number of reported additional
consultations by health-care practitioner
Usual care
(n= 253)
Intervention
(n= 256)
Total number
of visits (n= 509)
Mean difference
(95% CI); p-value
Outpatient visit: consultant led
Mean (SD) 0.48 (1.52) 0.34 (0.99) 121 usual 0.14 (–0.08 to 0.37);
p= 0.211
Median (25th centile, 75th centile) – – 86 HEELs
Minimum, maximum 0, 14 0, 8
Hospital outpatient visit (clinic lead unknown)
Mean (SD) 0.15 (1.78) 0.02 (0.12) 39 usual 0.14 (–0.08 to 0.36);
p= 0.215
Median (25th centile, 75th centile) – – 4 HEELs
Minimum, maximum 0, 28 0, 1
GP: home visit
Mean (SD) 0.04 (0.29) 0.03 (0.16) 10 usual 0.01 (–0.03 to 0.05);
p= 0.562
Median (25th centile, 75th centile) – – 7 HEELs
Minimum, maximum 0, 4 0, 1
GP: surgery appointment
Mean (SD) 0.21 (0.90) 0.20 (0.72) 53 usual 0.01 (–0.13 to 0.15);
p= 0.887
Median (25th centile, 75th centile) – – 51 HEELs
Minimum, maximum 0, 9 0, 5
GP: telephone consultation
Mean (SD) 0.004 (0.063) 0.008 (0.09) 1 usual –0.004 (–0.02 to 0.009);
p= 0.570
Median (25th centile, 75th centile) – – 2 HEELs
Minimum, maximum 0, 1 0, 1
Practice nurse
Mean (SD) 4.15 (10.11) 3.82 (11.07) 1049 usual 0.33 (–1.52 to 2.18);
p= 0.726
Median (25th centile, 75th centile) 0 (0, 1.5) 0 (0, 1) 977 HEELs
Minimum, maximum 0, 72 0, 86
SD, standard deviation.
Note
Of 250 reported outpatient consultations, 207 (83%) were reported as hospital doctor consultations and 43 (11%) were
reported as ‘hospital’ visits – clinic lead unknown.
Usual care: 160 reported outpatient visits; 76% consultant led, 24% clinic lead unknown.
Heels: 90 reported outpatient visits; 96% consultant led, 4% clinic lead unknown.
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TABLE 44 Costs of primary care and outpatient consultations (£)
Cost of reported additional
consultations by health-care
practitioner
Usual care
(n= 253)
Intervention
(n= 256)
Total number
of visits (n= 509)
Mean difference
(95% CI); p-value
Outpatient visit: consultant led
Mean (SD) 61.22 (194.71) 43.00 (127.02) 15,488 usual 18.22 (–0.10.38 to
46.81); p = 0.211
Median (25th centile, 75th centile) – – 11,008 HEELs
Minimum, maximum 0, 1792 0, 1024
Hospital outpatient visit (clinic lead unknown)
Mean (SD) 17.11 (197.65) 1.73 (13.79) 4329 usual 15.38 (–8.95 to 39.71);
p = 0.215
Median (25th centile, 75th centile) – – 444 HEELs
Minimum, maximum 0, 3108 0, 111
GP: home visit
Mean (SD) 4.55 (33.67) 3.15 (18.79) 1150 usual 1.40 (–3.34 to 6.14);
p = 0.562
Median (25th centile, 75th centile) – – 805 HEELs
Minimum, maximum 0, 460 0, 115
GP: surgery appointment
Mean (SD) 9.64 (41.58) 9.16 (33.20) 2438 usual 0.47 (–6.08 to 7.02);
p = 0.887
Median (25th centile, 75th centile) – – 2346 HEELs
Minimum, maximum 0, 414 0, 230
GP: telephone consultation
Mean (SD) 0.11 (1.76) 0.22 (2.47) 28 usual £0.11 (–0.48 to 0.27);
p = 0.570
Median (25th centile, 75th centile) – – 56 HEELs
Minimum, maximum 0, 28 0, 28
Practice nurse
Mean (SD) 42.50 (103.63) 39.12 (113.47) 10,752.25 usual £3.38 (–15.55 to 22.31);
p = 0.726
Median (25th centile, 75th centile) 0 (0, 15.38) 0 (0, 10.25) 10,014.25 HEELs
Minimum, maximum 0, 738 0, 881.50 10,752.25 usual
SD, standard deviation.
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TABLE 45 Hospital admission reported: mean cost per number of hospital admissions (£)
Number of admissions Usual care (n= 43)
Intervention
(n= 56)
Mean difference (95% CI);
p-value
One admission during the trial n= 26 n = 35
Mean (SD) 6094.96 (2707.94) 6154.20 (2267.10) –59.24 (–1335.53 to 1217.06);
p= 0.926
Median (25th centile,
75th centile)
3848, 7221 3848, 7221
Minimum, maximum 2326, 10,907 2326, 10,907
Two admissions during the trial n= 12 n = 16
Mean (SD) 11,493.67 (4490.71) 10,093.94 (5295.50) 1399.73 (–2502.30 to 5301.76);
p= 0.468
Median (25th centile,
75th centile)
8142.50, 14,676.75 4691.25, 14,316.75
Minimum, maximum 3848, 18,128 2326, 18,128
Three admissions during the trial n= 4 n = 4
Mean (SD) 11,905.75 (3247.15) 15,435.25 (4758.18) –3529.50 (–10,577.32 to 3518.32);
p= 0.266
Median (25th centile,
75th centile)
8539.25, 14,673 11,536.50, 20,170.75
Minimum, maximum 7696, 14,917 10,568, 21,976
Four admissions during the triala n= 1 n = 1
Mean (SD) 22,138 18,290 3848
Median (25th centile,
75th centile)
Minimum, maximum
SD, standard deviation.
a It is the total cost of four admissions for one patient in each group.
TABLE 46 Number of self-reported medication prescriptions by drug for infections related to the target foot ulcer
Drug name Usual care (n= 107) Intervention (n= 102)
Amoxicillin n= 13 n = 10
Mean (SD) 0.12 (0.527) 0.10 (0.330)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 4 0, 2
Augmentin n= 12 n = 12
Mean (SD) 0.11 (0.346) 0.12 (0.405)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 2 0, 2
Co-fluampicil n= 2 n = 0
Mean (SD) 0.02 (0.193)
Median (25th centile, 75th centile) –
Minimum, maximum 0, 2
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TABLE 46 Number of self-reported medication prescriptions by drug for infections related to the target
foot ulcer (continued )
Drug name Usual care (n= 107) Intervention (n= 102)
Ciprofloxacin n= 9 n = 5
Mean (SD) 0.08 (0.279) 0.05 (0.217)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 1 0, 1
Clarithromycin n= 14 n = 15
Mean (SD) 0.13 (0.391) 0.15 (0.408)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 2 0, 2
Clindamycin n= 27 n = 15
Mean (SD) 0.25 (0.551) 0.15 (0.383)
Median (25th centile, 75th centile) 0, 4 0, 2
Minimum, maximum
Co-amoxiclav n= 50 n = 61
Mean (SD) 0.47 (0.828) 0.60 (0.947)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 4 0, 5
Co-trimoxazole n= 2 n = 0
Mean (SD) 0.02 (0.136)
Median (25th centile, 75th centile) –
Minimum, maximum 0, 1
Doxycycline n= 17 n = 18
Mean (SD) 0.16 (0.367) 0.18 (0.432)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 1 0, 2
Erythromycin n= 2 n = 7
Mean (SD) 0.02 (0.136) 0.07 (0.254)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 1 0, 1
Fluloxacillin n= 62 n = 56
Mean (SD) 0.58 (1.055) 0.55 (0.897)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 8 0, 6
Fusidic acid n= 4 n = 4
Mean (SD) 0.04 (0.305) 0.04 (0.279)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 3 0, 2
continued
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TABLE 46 Number of self-reported medication prescriptions by drug for infections related to the target
foot ulcer (continued )
Drug name Usual care (n= 107) Intervention (n= 102)
Metronidazole n= 34 n = 21
Mean (SD) 0.32 (0.722) 0.21 (0.452)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 5 0, 2
Penicillin n= 4 n = 5
Mean (SD) 0.04 (0.191) 0.05 (0.294)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 1 0, 2
Rifampicin n= 7 n = 7
Mean (SD) 0.07 (0.284) 0.07 (0.290)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 2 0, 2
Trimethoprim n= 4 n = 5
Mean (SD) 0.04 (0.305) 0.05 (0.217)
Median (25th centile, 75th centile) – –
Minimum, maximum 0, 3 0, 1
Linezolid n= 2 n = 0
Mean (SD) 0.02 (0.136)
Median (25th centile, 75th centile) –
Minimum, maximum 0, 1
SD, standard deviation.
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